

# Bart Staels

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4207627/publications.pdf>

Version: 2024-02-01

799  
papers

87,669  
citations

197

149  
h-index

551

264  
g-index

830  
all docs

830  
docs citations

830  
times ranked

74605  
citing authors

#	ARTICLE	IF	CITATIONS
1	Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism. <i>Hepatology</i> , 2023, 77, 1287-1302.	7.3	3
2	Integrative study of diet-induced mouse models of NAFLD identifies PPAR $\alpha$ as a sexually dimorphic drug target. <i>Gut</i> , 2022, 71, 807-821.	12.1	26
3	Bile acids contribute to the development of non-alcoholic steatohepatitis in mice. <i>JHEP Reports</i> , 2022, 4, 100387.	4.9	28
4	Synthesis and biological studies of $\alpha$ -Polycerasoidol and $\alpha$ -trans- $\beta$ -Tocotrienolic acid derivatives as PPAR $\alpha$ and/or PPAR $\beta$ agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 53, 116532.	3.0	5
5	Identification of indole-based activators of insulin degrading enzyme. <i>European Journal of Medicinal Chemistry</i> , 2022, 228, 113982.	5.5	3
6	Posttranscriptional Regulation of the Human LDL Receptor by the U2-Spliceosome. <i>Circulation Research</i> , 2022, 130, 80-95.	4.5	9
7	Enterocyte superoxide dismutase 2 deletion drives obesity. <i>IScience</i> , 2022, 25, 103707.	4.1	4
8	Innovative transdermal delivery of insulin using gelatin methacrylate-based microneedle patches in mice and mini-pigs. <i>Nanoscale Horizons</i> , 2022, 7, 174-184.	8.0	21
9	The Circadian Clock and Obesity. <i>Handbook of Experimental Pharmacology</i> , 2022, , 29-56.	1.8	2
10	The conundrum of the functional relationship between transcription factors and chromatin. <i>Epigenomics</i> , 2022, , .	2.1	0
11	Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption. , 2022, 1, 299-312.		5
12	Circulating Monocyte Subsets and Transcatheter Aortic Valve Replacement. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5303.	4.1	4
13	Diabetes mellitus and cardiovascular mortality across the spectrum of aortic stenosis. <i>Heart</i> , 2022, 108, 1815-1821.	2.9	6
14	Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism. <i>Nutrients</i> , 2022, 14, 2707.	4.1	8
15	Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH). <i>Hepatology</i> , 2021, 73, 920-936.	7.3	39
16	Deletion of fibroblast activation protein provides atheroprotection. <i>Cardiovascular Research</i> , 2021, 117, 1060-1069.	3.8	20
17	Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease. <i>Acta Diabetologica</i> , 2021, 58, 319-327.	2.5	4
18	Apolipoprotein A5 controls fructose-induced metabolic dysregulation in mice. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 972-978.	2.6	3

#	ARTICLE	IF	CITATIONS
19	NASH-related increases in plasma bile acid levels depend on insulin resistance. <i>JHEP Reports</i> , 2021, 3, 100222.	4.9	24
20	Beyond the Rule of 5: Impact of PEGylation with Various Polymer Sizes on Pharmacokinetic Properties, Structure-Properties Relationships of mPEGylated Small Agonists of TGR5 Receptor. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 1593-1610.	6.4	9
21	Cholangiopathy and Biliary Fibrosis in Cyp2c70-Deficient Mice Are Fully Reversed by Ursodeoxycholic Acid. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1045-1069.	4.5	31
22	Alterations in Rev-ERB $\beta$ /BMAL1 ratio and glycated hemoglobin in rotating shift workers: the EuRhythDia study. <i>Acta Diabetologica</i> , 2021, 58, 1111-1117.	2.5	22
23	Light therapy improves diurnal blood pressure control in night shift workers via reduction of catecholamines: the EuRhythDia study. <i>Journal of Hypertension</i> , 2021, 39, 1678-1688.	0.5	11
24	Characterization of one anastomosis gastric bypass and impact of biliary and common limbs on bile acid and postprandial glucose metabolism in a minipig model. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E772-E783.	3.5	8
25	IFN $\beta$ -producing NK cells in adipose tissue are associated with hyperglycemia and insulin resistance in obese women. <i>International Journal of Obesity</i> , 2021, 45, 1607-1617.	3.4	8
26	Day-Time Declamping Is Associated with Better Outcomes in Kidney Transplantation: The Circarein Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2322.	2.4	8
27	Vascular Endothelial Damage in the Pathogenesis of Organ Injury in Severe COVID-19. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1760-1773.	2.4	82
28	PPARs in liver physiology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166097.	3.8	33
29	PPAR control of metabolism and cardiovascular functions. <i>Nature Reviews Cardiology</i> , 2021, 18, 809-823.	13.7	299
30	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. <i>Journal of Hepatology</i> , 2021, 74, 1344-1354.	3.7	77
31	Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms. <i>Toxicology</i> , 2021, 459, 152845.	4.2	40
32	Hypothalamic bile acid-TGR5 signaling protects from obesity. <i>Cell Metabolism</i> , 2021, 33, 1483-1492.e10.	16.2	79
33	Regulation of PPAR $\alpha$ by APP in Alzheimer disease affects the pharmacological modulation of synaptic activity. <i>JCI Insight</i> , 2021, 6, .	5.0	8
34	Hepatic sexual dimorphism " implications for non-alcoholic fatty liver disease. <i>Nature Reviews Endocrinology</i> , 2021, 17, 662-670.	9.6	41
35	The ALGOVUE Clinical Trial: Effects of the Daily Consumption of Eggs Enriched with Lutein and Docosahexaenoic Acid on Plasma Composition and Macular Pigment Optical Density. <i>Nutrients</i> , 2021, 13, 3347.	4.1	9
36	An optimized protocol with a stepwise approach to identify specific nuclear receptor ligands from cultured mammalian cells. <i>STAR Protocols</i> , 2021, 2, 100658.	1.2	2

#	ARTICLE	IF	CITATIONS
37	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	2.2	303
38	Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154844.	3.4	20
39	Synthesis of 2-Prenylated Alkoxyated Benzopyrans by Horner-Wadsworth-Emmons Olefination with PPAR $\alpha$ Agonist Activity. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1783-1786.	2.8	5
40	Lipidomics and metabolomics signatures of SARS-CoV-2 mediators/receptors in peripheral leukocytes, jejunum and colon. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 6080-6089.	4.1	7
41	The hepatic compensatory response to elevated systemic sulfide promotes diabetes. <i>Cell Reports</i> , 2021, 37, 109958.	6.4	9
42	Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 808603.	2.9	9
43	Peroxisomal $\beta$ -oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis. <i>Nature Metabolism</i> , 2021, 3, 1648-1661.	11.9	70
44	Electrothermal patches driving the transdermal delivery of insulin. <i>Nanoscale Horizons</i> , 2020, 5, 663-670.	8.0	30
45	Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets. <i>Diabetes</i> , 2020, 69, 902-914.	0.6	42
46	Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes. <i>Metabolism: Clinical and Experimental</i> , 2020, 103, 154042.	3.4	21
47	Control of Cell Identity by the Nuclear Receptor HNF4 in Organ Pathophysiology. <i>Cells</i> , 2020, 9, 2185.	4.1	40
48	Timed physical exercise does not influence circadian rhythms and glucose tolerance in rotating night shift workers: The EuRhythDia study. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412095061.	2.0	8
49	CDKN2A/p16INK4a suppresses hepatic fatty acid oxidation through the AMPK $\alpha$ -SIRT1-PPAR $\alpha$ signaling pathway. <i>Journal of Biological Chemistry</i> , 2020, 295, 17310-17322.	3.4	17
50	Dysregulated lipid metabolism links NAFLD to cardiovascular disease. <i>Molecular Metabolism</i> , 2020, 42, 101092.	6.5	197
51	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 970-985.	8.1	142
52	Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19. <i>Circulation</i> , 2020, 142, 1881-1884.	1.6	69
53	GIANT: galaxy-based tool for interactive analysis of transcriptomic data. <i>Scientific Reports</i> , 2020, 10, 19835.	3.3	11
54	Deletion of the nuclear receptor ROR $\alpha$ in macrophages does not modify the development of obesity, insulin resistance and NASH. <i>Scientific Reports</i> , 2020, 10, 21095.	3.3	6

#	ARTICLE	IF	CITATIONS
55	Saturated Fatty Acids Promote GDF15 Expression in Human Macrophages through the PERK/eIF2/CHOP Signaling Pathway. <i>Nutrients</i> , 2020, 12, 3771.	4.1	14
56	Altered PPAR $\beta$ Expression Promotes Myelin-Induced Foam Cell Formation in Macrophages in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9329.	4.1	16
57	Human Aortic Valve Interstitial Cells Display Proangiogenic Properties During Calcific Aortic Valve Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 41, 415-429.	2.4	12
58	Perspectives on the use of super-enhancers as a defining feature of cell/tissue-identity genes. <i>Epigenomics</i> , 2020, 12, 715-723.	2.1	5
59	Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1328-1338.	4.4	26
60	Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment. <i>Molecular Metabolism</i> , 2020, 36, 100976.	6.5	46
61	Analysis of the association of MPO and MMP-9 with stroke severity and outcome. <i>Neurology</i> , 2020, 95, e97-e108.	1.1	42
62	Pirfenidone Is an Agonistic Ligand for PPAR $\alpha$ and Improves NASH by Activation of SIRT1/LKB1/pAMPK. <i>Hepatology Communications</i> , 2020, 4, 434-449.	4.3	33
63	Differential unfolded protein response in skeletal muscle from non-diabetic glucose tolerant or intolerant patients with obesity before and after bariatric surgery. <i>Acta Diabetologica</i> , 2020, 57, 819-826.	2.5	1
64	Microbiome Modulation of the Host Adaptive Immunity through Bile Acid Modification. <i>Cell Metabolism</i> , 2020, 31, 445-447.	16.2	22
65	The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids. <i>Scientific Reports</i> , 2020, 10, 174.	3.3	45
66	Effect of 6-Benzoyl-benzothiazol-2-one scaffold on the pharmacological profile of $\beta$ -alkoxyphenylpropionic acid derived PPAR agonists. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 524-538.	5.2	4
67	Sirt6 deletion in bone marrow-derived cells increases atherosclerosis – Central role of macrophage scavenger receptor 1. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 139, 24-32.	1.9	26
68	Clinical significance of electrocardiographic markers of myocardial damage prior to aortic valve replacement. <i>International Journal of Cardiology</i> , 2020, 307, 130-135.	1.7	10
69	Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. <i>Nature Communications</i> , 2020, 11, 1891.	12.8	63
70	Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2311-2321.	3.6	39
71	Endoplasmic reticulum stress actively suppresses hepatic molecular identity in damaged liver. <i>Molecular Systems Biology</i> , 2020, 16, e9156.	7.2	22
72	Obesity Paradox in the Clinical Significance of Effective Prosthetic Orifice Area After Aortic Valve Replacement. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 208-210.	5.3	14

#	ARTICLE	IF	CITATIONS
73	The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release. <i>Cell Reports</i> , 2019, 28, 1447-1454.e4.	6.4	25
74	Mathematical models converge on PGC1 $\beta$ as the key metabolic integrator of SIRT1 and AMPK regulation of the circadian clock. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 13171-13172.	7.1	7
75	FXR overexpression alters adipose tissue architecture in mice and limits its storage capacity leading to metabolic derangements. <i>Journal of Lipid Research</i> , 2019, 60, 1547-1561.	4.2	19
76	Glycogen Dynamics Drives Lipid Droplet Biogenesis during Brown Adipocyte Differentiation. <i>Cell Reports</i> , 2019, 29, 1410-1418.e6.	6.4	31
77	Transcription profiling in the liver of undernourished male rat offspring reveals altered lipid metabolism pathways and predisposition to hepatic steatosis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E1094-E1107.	3.5	6
78	Mechanisms Underlying the Functional Cooperation Between PPAR $\beta$ and GR $\beta$ to Attenuate Inflammatory Responses. <i>Frontiers in Immunology</i> , 2019, 10, 1769.	4.8	12
79	Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model. <i>Neurobiology of Disease</i> , 2019, 125, 14-22.	4.4	16
80	Hepatic PPAR $\beta$ is critical in the metabolic adaptation to sepsis. <i>Journal of Hepatology</i> , 2019, 70, 963-973.	3.7	53
81	Near-infrared light activatable hydrogels for metformin delivery. <i>Nanoscale</i> , 2019, 11, 15810-15820.	5.6	30
82	Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients. <i>BMC Medical Genomics</i> , 2019, 12, 80.	1.5	22
83	Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution. <i>Nature Metabolism</i> , 2019, 1, 604-614.	11.9	102
84	FRI-355-Elafibranor, a drug candidate for first line NASH monotherapy and a universal backbone for drug combination treatment. <i>Journal of Hepatology</i> , 2019, 70, e551.	3.7	2
85	Metabolic and Innate Immune Cues Merge into a Specific Inflammatory Response via the UPR. <i>Cell</i> , 2019, 177, 1201-1216.e19.	28.9	100
86	Dietary Sargassum fusiforme improves memory and reduces amyloid plaque load in an Alzheimer's disease mouse model. <i>Scientific Reports</i> , 2019, 9, 4908.	3.3	51
87	The circadian clock and liver function in health and disease. <i>Journal of Hepatology</i> , 2019, 71, 200-211.	3.7	128
88	Liver-specific ROR $\beta$ deletion does not affect the metabolic susceptibility to western style diet feeding. <i>Molecular Metabolism</i> , 2019, 23, 82-87.	6.5	4
89	Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR $\beta$ . <i>Nature Communications</i> , 2019, 10, 1684.	12.8	48
90	Understanding lipid metabolism through hepatic steat-omics. <i>Nature Reviews Endocrinology</i> , 2019, 15, 321-322.	9.6	1

#	ARTICLE	IF	CITATIONS
91	The LPS/D-Galactosamine-Induced Fulminant Hepatitis Model to Assess the Role of Ligand-Activated Nuclear Receptors on the NLRP3 Inflammasome Pathway In Vivo. <i>Methods in Molecular Biology</i> , 2019, 1951, 189-207.	0.9	7
92	Synthesis of benzopyran derivatives as PPAR $\alpha$ and/or PPAR $\beta$ activators. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 115162.	3.0	6
93	Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell?. <i>Current Opinion in Lipidology</i> , 2019, 30, 244-254.	2.7	39
94	ATF6 $\alpha$ downregulation of PPAR $\alpha$ promotes lipotoxicity-induced tubulointerstitial fibrosis. <i>Kidney International</i> , 2019, 95, 577-589.	5.2	86
95	Epicardial fat amount is associated with the magnitude of left ventricular remodeling in aortic stenosis. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 267-273.	1.5	13
96	Keratinocyte Expression of A20/TNFAIP3 Controls Skin Inflammation Associated with Atopic Dermatitis and Psoriasis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 135-145.	0.7	42
97	Sex-regulated gene dosage effect of PPAR $\alpha$ on synaptic plasticity. <i>Life Science Alliance</i> , 2019, 2, e201800262.	2.8	16
98	Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice. <i>Gastroenterology</i> , 2018, 154, 1449-1464.e20.	1.3	144
99	Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1310-1321.	0.6	64
100	Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. <i>Gut</i> , 2018, 67, 271-283.	12.1	150
101	Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbs antagonism: a single-centre propensity-matched cohort study and a randomised study. <i>Lancet</i> , The, 2018, 391, 59-69.	13.7	244
102	Risperidone-induced metabolic dysfunction is attenuated by Curcuma longa extract administration in mice. <i>Metabolic Brain Disease</i> , 2018, 33, 63-77.	2.9	11
103	Organizing combinatorial transcription factor recruitment at cis-regulatory modules. <i>Transcription</i> , 2018, 9, 233-239.	3.1	10
104	Combinatorial regulation of hepatic cytoplasmic signaling and nuclear transcriptional events by the OGT/REV-ERB complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11033-E11042.	7.1	35
105	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association "European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	2.2	171
106	Time to Check the Clock in Cardiovascular Research and Medicine. <i>Circulation Research</i> , 2018, 123, 648-650.	4.5	12
107	Retinoids Issued from Hepatic Stellate Cell Lipid Droplet Loss as Potential Signaling Molecules Orchestrating a Multicellular Liver Injury Response. <i>Cells</i> , 2018, 7, 137.	4.1	30
108	Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. <i>Atherosclerosis</i> , 2018, 278, 82-90.	0.8	27

#	ARTICLE	IF	CITATIONS
109	Daytime variations in perioperative myocardial injury – Authors' reply. <i>Lancet, The</i> , 2018, 391, 2106.	13.7	0
110	Molecular Actions of PPAR $\alpha$ in Lipid Metabolism and Inflammation. <i>Endocrine Reviews</i> , 2018, 39, 760-802.	20.1	420
111	Peri-operative acute kidney injury upon cardiac surgery time-of-day. <i>International Journal of Cardiology</i> , 2018, 272, 54-59.	1.7	9
112	The Nuclear Receptor Rev-erb $\alpha$ Controls the Development of Vascular Calcification. <i>Atherosclerosis Supplements</i> , 2018, 32, 107.	1.2	0
113	The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis. <i>Journal of Hepatology</i> , 2018, 69, 1099-1109.	3.7	40
114	Circadian misalignment induces fatty acid metabolism gene profiles and compromises insulin sensitivity in human skeletal muscle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 7789-7794.	7.1	138
115	A deep-learning approach for pattern recognition allows rapid and reproducible quantification of histological NASH parameters: Integration into the QuPath platform. <i>Journal of Hepatology</i> , 2018, 68, S123.	3.7	3
116	Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2106-2118.	2.8	86
117	MuscleJ: a high-content analysis method to study skeletal muscle with a new Fiji tool. <i>Skeletal Muscle</i> , 2018, 8, 25.	4.2	105
118	Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity. <i>JCI Insight</i> , 2018, 3, .	5.0	4
119	Alternative macrophages in atherosclerosis: not always protective!. <i>Journal of Clinical Investigation</i> , 2018, 128, 910-912.	8.2	37
120	Development and implementation of a cell-based assay to discover agonists of the nuclear receptor REV-ERB $\alpha$ . <i>Journal of Biological Methods</i> , 2018, 5, e94.	0.6	10
121	Rev-erb $\alpha$ : une cible thérapeutique contre la perte de masse musculaire ?. <i>Les Cahiers De Myologie</i> , 2018, , 43-44.	0.0	0
122	Roux-en-Y gastric bypass increases systemic but not portal bile acid concentrations by decreasing hepatic bile acid uptake in minipigs. <i>International Journal of Obesity</i> , 2017, 41, 664-668.	3.4	21
123	Topical ivermectin improves allergic skin inflammation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1212-1221.	5.7	44
124	The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model. <i>Diabetes</i> , 2017, 66, 1030-1040.	0.6	119
125	Inactivation of the Nuclear Orphan Receptor COUP-TFII by Small Chemicals. <i>ACS Chemical Biology</i> , 2017, 12, 654-663.	3.4	13
126	Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2017, 152, 1679-1694.e3.	1.3	630



#	ARTICLE	IF	CITATIONS
127	Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. <i>Atherosclerosis</i> , 2017, 257, 186-194.	0.8	17
128	The logic of transcriptional regulator recruitment architecture at cis-regulatory modules controlling liver functions. <i>Genome Research</i> , 2017, 27, 985-996.	5.5	22
129	Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity. <i>Circulation Research</i> , 2017, 121, 19-30.	4.5	76
130	Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4185-4211.	6.4	48
131	Anti-diabetic activity of fused PPAR $\beta$ -SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. <i>European Journal of Medicinal Chemistry</i> , 2017, 137, 310-326.	5.5	7
132	Mitochondria and endoplasmic reticulum: Targets for a better insulin sensitivity in skeletal muscle?. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2017, 1862, 901-916.	2.4	13
133	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. <i>American Journal of Cardiology</i> , 2017, 120, S28-S36.	1.6	45
134	Drug repurposing screen identifies novel small molecule compounds with potent antifibrotic properties. <i>Journal of Hepatology</i> , 2017, 66, S605.	3.7	4
135	The PPAR $\alpha$ -regulated dermatopontin is an important contributor to the liver fibrotic response in mouse models and has relevance to fibrosis progression in non-alcoholic fatty liver disease patients. <i>Journal of Hepatology</i> , 2017, 66, S165.	3.7	0
136	Paired biopsy analysis of human liver transcriptome before and 1 year after bariatric surgery identifies a restricted set of inflammation- and extracellular matrix-related genes as pivotal in NASH and fibrosis pathogenesis. <i>Journal of Hepatology</i> , 2017, 66, S593-S594.	3.7	0
137	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. <i>American Journal of Medicine</i> , 2017, 130, S30-S39.	1.5	56
138	Leptin induces osteoblast differentiation of human valvular interstitial cells via the Akt and ERK pathways. <i>Acta Diabetologica</i> , 2017, 54, 551-560.	2.5	20
139	PPAR $\beta$ in macrophages and atherosclerosis. <i>Biochimie</i> , 2017, 136, 59-64.	2.6	26
140	DHA-derived oxylipins, neuroprostanes and protectins, differentially and dose-dependently modulate the inflammatory response in human macrophages: Putative mechanisms through PPAR activation. <i>Free Radical Biology and Medicine</i> , 2017, 103, 146-154.	2.9	42
141	The RBM14/CoAA-interacting, long intergenic non-coding RNA Paral1 regulates adipogenesis and coactivates the nuclear receptor PPAR $\beta$ . <i>Scientific Reports</i> , 2017, 7, 14087.	3.3	33
142	Fasting the Microbiota to Improve Metabolism?. <i>Cell Metabolism</i> , 2017, 26, 584-585.	16.2	9
143	Role of the nuclear receptor Rev-erb- $\alpha$ in the development of vascular calcification. <i>Atherosclerosis</i> , 2017, 263, e19.	0.8	0
144	375 Psoriasis-like inflammation in K14PPAR $\beta$ transgenic mice selectively overexpressing PPAR $\beta$ in keratinocytes. <i>Journal of Investigative Dermatology</i> , 2017, 137, S256.	0.7	0

#	ARTICLE	IF	CITATIONS
145	The tumour suppressor CDKN2A/p16INK4a regulates adipogenesis and bone marrow-dependent development of perivascular adipose tissue. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 516-524.	2.0	16
146	Ffar2 expression regulates leukaemic cell growth in vivo. <i>British Journal of Cancer</i> , 2017, 117, 1336-1340.	6.4	12
147	Circadian control of metabolism and pathological consequences of clock perturbations. <i>Biochimie</i> , 2017, 143, 42-50.	2.6	26
148	Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3783-3794.	3.6	78
149	Tau deletion promotes brain insulin resistance. <i>Journal of Experimental Medicine</i> , 2017, 214, 2257-2269.	8.5	158
150	A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH. <i>Journal of Hepatology</i> , 2017, 66, S110.	3.7	5
151	Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis. <i>Journal of Hepatology</i> , 2017, 66, S110-S111.	3.7	3
152	Retrograde cholesterol transport in the human Caco-2/TC7 cell line: a model to study trans-intestinal cholesterol excretion in atherogenic and diabetic dyslipidemia. <i>Acta Diabetologica</i> , 2017, 54, 191-199.	2.5	10
153	Intestinal bile acid receptors are key regulators of glucose homeostasis. <i>Proceedings of the Nutrition Society</i> , 2017, 76, 192-202.	1.0	27
154	PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. <i>Nature Reviews Endocrinology</i> , 2017, 13, 36-49.	9.6	509
155	Rev-erb- $\alpha$ regulates atrophy-related genes to control skeletal muscle mass. <i>Scientific Reports</i> , 2017, 7, 14383.	3.3	39
156	Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPAR $\alpha$ -regulated dermatopontin. <i>JCI Insight</i> , 2017, 2, .	5.0	96
157	Distinct but complementary contributions of PPAR isotypes to energy homeostasis. <i>Journal of Clinical Investigation</i> , 2017, 127, 1202-1214.	8.2	270
158	Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis. <i>PPAR Research</i> , 2016, 2016, 1-5.	2.4	8
159	Peroxisome Proliferator-Activated Receptor $\alpha$ Induces the Expression of Tissue Factor Pathway Inhibitor-1 (TFPI-1) in Human Macrophages. <i>PPAR Research</i> , 2016, 2016, 1-9.	2.4	4
160	Metabolic effects of bile acid sequestration. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 138-144.	2.3	9
161	Comment on Patel et al. ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity. <i>Diabetes</i> 2016;65:85â€“95. <i>Diabetes</i> , 2016, 65, e1-e2.	0.6	12
162	Demonstration of a day-night rhythm in human skeletal muscle oxidative capacity. <i>Molecular Metabolism</i> , 2016, 5, 635-645.	6.5	136

#	ARTICLE	IF	CITATIONS
163	Transducin-like enhancer of split-1 is expressed and functional in human macrophages. <i>FEBS Letters</i> , 2016, 590, 43-52.	2.8	6
164	Innate lymphoid cells contribute to allergic airway disease exacerbation by obesity. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1309-1318.e11.	2.9	83
165	Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans. <i>International Journal of Obesity</i> , 2016, 40, 1260-1267.	3.4	61
166	PLPNA3 Status in Nash is Associated with Increased Histological Severity at Baseline but Not with Response to Therapy in the Golden-505 Elafibranor Trial. <i>Journal of Hepatology</i> , 2016, 64, S147.	3.7	2
167	A Post-Hoc Analysis of the Golden505 Trial Demonstrates Histological and Cardiometabolic Efficacy of Elafibranor-120 Mg in Patients with Moderate or Severe Nash That Are Eligible for Pharmacotherapy. <i>Journal of Hepatology</i> , 2016, 64, S192.	3.7	0
168	ROR $\gamma$ t Inhibition in the Liver Prevents Hepatic Fibrosis Progression, a Proof of Concept Study with a Potent, First in Class, Hepatocentric ROR $\gamma$ t Inverse Agonist. <i>Journal of Hepatology</i> , 2016, 64, S523.	3.7	1
169	The Identification of Novel Small Molecule Compounds with Potent Anti-Fibrotic Properties by Phenotypic Screening of Primary Human Stellate Cells. <i>Journal of Hepatology</i> , 2016, 64, S712.	3.7	0
170	A New Method including the Quantification of Circulating Mirnas Allows the Efficient Identification of Nash Patients at Risk who should be Treated. <i>Journal of Hepatology</i> , 2016, 64, S717.	3.7	2
171	Impaired histone deacetylases 5 and 6 expression mimics the effects of obesity and hypoxia on adipocyte function. <i>Molecular Metabolism</i> , 2016, 5, 1200-1207.	6.5	25
172	An oxidative stress paradox: time for a conceptual change?. <i>Diabetologia</i> , 2016, 59, 2514-2517.	6.3	5
173	ORP4L Facilitates Macrophage Survival via G-Protein-Coupled Signaling. <i>Circulation Research</i> , 2016, 119, 1296-1312.	4.5	26
174	Relationship between Baseline Hepatic Disease Severity and the Cardiometabolic and Anti-Inflammatory Effects of Elafibranor in Patients with Non-Alcoholic Steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, S499-S500.	3.7	1
175	Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPAR $\gamma$ . <i>Nucleic Acids Research</i> , 2016, 44, 10539-10553.	14.5	56
176	Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2016, 375, 335-344.	27.0	128
177	Synchronized human skeletal myotubes of lean, obese and type 2 diabetic patients maintain circadian oscillation of clock genes. <i>Scientific Reports</i> , 2016, 6, 35047.	3.3	35
178	Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2324-2333.	2.4	24
179	Omentin-1, epicardial fat and coronary artery disease. <i>Atherosclerosis</i> , 2016, 255, 224-225.	0.8	0
180	A Mathematical Model of the Liver Circadian Clock Linking Feeding and Fasting Cycles to Clock Function. <i>Cell Reports</i> , 2016, 17, 1087-1097.	6.4	74

#	ARTICLE	IF	CITATIONS
181	Perilipin2/adipophilin and ApoA-1 team up to combat atherosclerosis. <i>Cardiovascular Research</i> , 2016, 109, 193-195.	3.8	7
182	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
183	Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. <i>Annual Review of Physiology</i> , 2016, 78, 181-205.	13.1	302
184	Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1. <i>Gastroenterology</i> , 2016, 150, 650-658.	1.3	41
185	The novel selective PPAR $\alpha$ modulator (SPPARM $\alpha$ ) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. <i>Atherosclerosis</i> , 2016, 249, 200-208.	0.8	107
186	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor $\alpha$ and $\beta$ , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5.	1.3	847
187	Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPAR $\alpha$ expression. <i>Gut</i> , 2016, 65, 1882-1894.	12.1	140
188	Skeletal muscle functions around the clock. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 39-46.	4.4	40
189	Cholesteryl ester transfer protein (CETP): A Kupffer cell marker linking hepatic inflammation with atherogenic dyslipidemia?. <i>Hepatology</i> , 2015, 62, 1659-1661.	7.3	6
190	Bariatric surgery, lipoprotein metabolism and cardiovascular risk. <i>Current Opinion in Lipidology</i> , 2015, 26, 317-324.	2.7	15
191	The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation. <i>Obesity</i> , 2015, 23, 2066-2074.	3.0	196
192	Temporal changes in bile acid levels and 12 $\alpha$ -hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. <i>International Journal of Obesity</i> , 2015, 39, 806-813.	3.4	79
193	Structural and functional changes in HDL with low grade and chronic inflammation. <i>International Journal of Cardiology</i> , 2015, 188, 111-116.	1.7	60
194	The Sirt1 activator SRT3025 provides atheroprotection in ApoE $^{-/-}$ mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. <i>European Heart Journal</i> , 2015, 36, 51-59.	2.2	117
195	Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs?. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 176-184.	7.1	137
196	M1 and M2 macrophage proteolytic and angiogenic profile analysis in atherosclerotic patients reveals a distinctive profile in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 279-289.	2.0	38
197	Molecular mechanism of PPAR $\alpha$ action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015, 62, 720-733.	3.7	1,028
198	The ubiquitous transcription factor CTCF promotes lineage-specific epigenomic remodeling and establishment of transcriptional networks driving cell differentiation. <i>Nucleus</i> , 2015, 6, 15-18.	2.2	7

#	ARTICLE	IF	CITATIONS
199	Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2473-2478.	7.1	310
200	Rapid and Body Weight-Independent Improvement of Endothelial and High-Density Lipoprotein Function After Roux-en-Y Gastric Bypass. <i>Circulation</i> , 2015, 131, 871-881.	1.6	103
201	The coronary artery disease-associated gene C6ORF105 is expressed in human macrophages under the transcriptional control of PPAR $\beta$ . <i>FEBS Letters</i> , 2015, 589, 461-466.	2.8	17
202	PPAR $\beta$ gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2015, 63, 164-173.	3.7	270
203	Adventitial Tertiary Lymphoid Organs as Potential Source of MicroRNA Biomarkers for Abdominal Aortic Aneurysm. <i>International Journal of Molecular Sciences</i> , 2015, 16, 11276-11293.	4.1	28
204	Role of the nuclear receptor Rev-erb-alpha in the development of atherosclerosis. <i>Atherosclerosis</i> , 2015, 241, e6.	0.8	1
205	The neuron-derived orphan receptor 1 (NOR1) is induced upon human alternative macrophage polarization and stimulates the expression of markers of the M2 phenotype. <i>Atherosclerosis</i> , 2015, 241, 18-26.	0.8	30
206	The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity. <i>Cell Metabolism</i> , 2015, 22, 418-426.	16.2	342
207	Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. <i>Nature Communications</i> , 2015, 6, 7629.	12.8	274
208	Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. <i>Nature Medicine</i> , 2015, 21, 512-517.	30.7	536
209	MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. <i>Journal of Clinical Investigation</i> , 2015, 125, 2497-2509.	8.2	195
210	Atherosclerosis: Recent trials, new targets and future directions. <i>International Journal of Cardiology</i> , 2015, 192, 72-81.	1.7	28
211	SREBF2 -Embedded mir33 Links the Nuclear Bile Acid Receptor FXR to Cholesterol and Lipoprotein Metabolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 748-749.	2.4	5
212	von Willebrand Factor as a Biological Sensor of Blood Flow to Monitor Percutaneous Aortic Valve Interventions. <i>Circulation Research</i> , 2015, 116, 1193-1201.	4.5	72
213	Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice. <i>Nature Communications</i> , 2015, 6, 8250.	12.8	71
214	From cardiac mitochondrial dysfunction to clinical arrhythmias. <i>International Journal of Cardiology</i> , 2015, 184, 597-599.	1.7	12
215	Ketone Body Therapy Protects From Lipotoxicity and Acute Liver Failure Upon Ppar $\beta$ Deficiency. <i>Molecular Endocrinology</i> , 2015, 29, 1134-1143.	3.7	33
216	Screening strategy to generate cell specific recombination: a case report with the RIP-Cre mice. <i>Transgenic Research</i> , 2015, 24, 803-812.	2.4	8

#	ARTICLE	IF	CITATIONS
217	Gamma radiation production using channeled positron annihilation in crystals. <i>Laser Physics Letters</i> , 2015, 12, 076002.	1.4	2
218	Meta-Analysis of Abdominal Aortic Aneurysm in Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2015, 116, 1451-1456.	1.6	31
219	Nuclear bile acid signaling through the farnesoid X receptor. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 1631-1650.	5.4	92
220	Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme. <i>European Journal of Medicinal Chemistry</i> , 2015, 90, 547-567.	5.5	24
221	Macrophage subsets in atherosclerosis. <i>Nature Reviews Cardiology</i> , 2015, 12, 10-17.	13.7	501
222	Emerging Small Molecule Drugs. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 617-630.	1.8	7
223	GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1441-1448.	4.1	27
224	Liver X receptor activation decreases chylomicron assembly and improves post-prandial triglyceridemia via intestinal sr-bi downregulation. <i>Atherosclerosis</i> , 2014, 235, e33.	0.8	0
225	PPAR $\delta$ is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 294-302.	1.9	12
226	Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). <i>Hepatology</i> , 2014, 59, 2022-2033.	7.3	55
227	Neuroprostanes, produced by free-radical mediated peroxidation of DHA, inhibit the inflammatory response of human macrophages. <i>Free Radical Biology and Medicine</i> , 2014, 75, S15.	2.9	14
228	The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 440-447.	2.0	31
229	A dynamic CTCF chromatin binding landscape promotes DNA hydroxymethylation and transcriptional induction of adipocyte differentiation. <i>Nucleic Acids Research</i> , 2014, 42, 10943-10959.	14.5	71
230	Impact of Endotoxin Challenge in Obese Pigs. <i>Shock</i> , 2014, 41, 546-553.	2.1	10
231	Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. <i>Journal of Clinical Investigation</i> , 2014, 124, 1037-1051.	8.2	121
232	Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly. <i>Journal of Lipid Research</i> , 2014, 55, 41-52.	4.2	15
233	HDL does not influence the polarization of human monocytes toward an alternative phenotype. <i>International Journal of Cardiology</i> , 2014, 172, 179-184.	1.7	23
234	DCo(H2)ding the Metabolic Functions of SIRT1 in the Intestine. <i>Gastroenterology</i> , 2014, 146, 893-896.	1.3	1

#	ARTICLE	IF	CITATIONS
235	Failing FXR expression in the liver links aging to hepatic steatosis. <i>Journal of Hepatology</i> , 2014, 60, 689-690.	3.7	15
236	P263 STEATOSIS-INDEPENDENT PREVENTION OF LIVER FIBROSIS VIA THE TRANSREPRESSIVE ACTIVITY OF PPAR $\alpha$ . <i>Journal of Hepatology</i> , 2014, 60, S152-S153.	3.7	0
237	Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid- $\beta$ hydrolysis. <i>European Journal of Medicinal Chemistry</i> , 2014, 79, 184-193.	5.5	27
238	Alternative human liver transcripts of TCF7L2 bind to the gluconeogenesis regulator HNF4 $\beta$ at the protein level. <i>Diabetologia</i> , 2014, 57, 785-796.	6.3	33
239	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014, 232, 346-360.	0.8	419
240	<i>p16<sup>INK4a</sup></i> Regulates Fasting-Induced Hepatic Gluconeogenesis Through the PKA-CREB-PGC1 $\beta$ Pathway. <i>Diabetes</i> , 2014, 63, 3199-3209.	0.6	36
241	Cell-Specific Dysregulation of MicroRNA Expression in Obese White Adipose Tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2821-2833.	3.6	55
242	CX3CL1 (fractalkine) and its receptor CX3CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin. <i>Journal of Experimental Medicine</i> , 2014, 211, 1185-1196.	8.5	49
243	Peroxisome Proliferator-activated Receptor $\beta$ Regulates Genes Involved in Insulin/Insulin-like Growth Factor Signaling and Lipid Metabolism during Adipogenesis through Functionally Distinct Enhancer Classes. <i>Journal of Biological Chemistry</i> , 2014, 289, 708-722.	3.4	39
244	Adipose Tissue Macrophages (ATM) of obese patients are releasing increased levels of prolactin during an inflammatory challenge: A role for prolactin in diabetes?. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 584-593.	3.8	26
245	HDL in Children with CKD Promotes Endothelial Dysfunction and an Abnormal Vascular Phenotype. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2658-2668.	6.1	97
246	Macrophage phenotypes in atherosclerosis. <i>Immunological Reviews</i> , 2014, 262, 153-166.	6.0	454
247	<i>SULF2</i> strongly predisposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus. <i>Obesity</i> , 2014, 22, 1309-1316.	3.0	33
248	Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone—a factorial study. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 223-230.	4.4	33
249	<i>Giardia muris</i> Infection in Mice Is Associated with a Protective Interleukin 17A Response and Induction of Peroxisome Proliferator-Activated Receptor Alpha. <i>Infection and Immunity</i> , 2014, 82, 3333-3340.	2.2	56
250	Effects of the PPAR- $\alpha$ Agonist Fenofibrate on Acute and Short-Term Consequences of Brain Ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 542-551.	4.3	51
251	Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization. <i>Trends in Endocrinology and Metabolism</i> , 2014, 25, 235-244.	7.1	43
252	Myocardial Contractile Dysfunction Is Associated With Impaired Mitochondrial Function and Dynamics in Type 2 Diabetic but Not in Obese Patients. <i>Circulation</i> , 2014, 130, 554-564.	1.6	237

#	ARTICLE	IF	CITATIONS
253	miR-206 controls LXR $\alpha$ expression and promotes LXR-mediated cholesterol efflux in macrophages. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2014, 1841, 827-835.	2.4	35
254	Macrophage Phenotypes and Their Modulation in Atherosclerosis. <i>Circulation Journal</i> , 2014, 78, 1775-1781.	1.6	163
255	Macrophage-specific inactivation of the nuclear receptor ROR-alpha leads to increased atherosclerosis in mouse. <i>Atherosclerosis</i> , 2014, 235, e20.	0.8	0
256	MiR-206 controls LXR-alpha expression and promotes LXR-mediated cholesterol efflux in macrophages. <i>Atherosclerosis</i> , 2014, 235, e39.	0.8	0
257	Apolipoprotein a5-deficiency promotes cardiac glucose metabolism and protects against acute myocardial stresses. <i>Atherosclerosis</i> , 2014, 235, e45.	0.8	0
258	The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. <i>Hepatology</i> , 2014, 60, 1593-1606.	7.3	116
259	Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Hepatology</i> , 2014, 59, 121-129.	7.3	141
260	O-GlcNAcylation Links ChREBP and FXR to Glucose-Sensing. <i>Frontiers in Endocrinology</i> , 2014, 5, 230.	3.5	28
261	Beneficial Metabolic Effects of Rapamycin Are Associated with Enhanced Regulatory Cells in Diet-Induced Obese Mice. <i>PLoS ONE</i> , 2014, 9, e92684.	2.5	51
262	Sox17 Regulates Liver Lipid Metabolism and Adaptation to Fasting. <i>PLoS ONE</i> , 2014, 9, e104925.	2.5	15
263	Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedures. <i>Blood</i> , 2014, 124, 474-474.	1.4	0
264	The Hepatic Orosomucoid/ $\alpha$ 1-Acid Glycoprotein Gene Cluster Is Regulated by the Nuclear Bile Acid Receptor FXR. <i>Endocrinology</i> , 2013, 154, 3690-3701.	2.8	24
265	Rev-erb- $\alpha$ modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. <i>Nature Medicine</i> , 2013, 19, 1039-1046.	30.7	361
266	PPAR SUMOylation: Some Useful Experimental Tips. <i>Methods in Molecular Biology</i> , 2013, 952, 145-161.	0.9	1
267	A gene variant of <i>PNPLA3</i> , but not of <i>APOC3</i> , is associated with histological parameters of NAFLD in an obese population. <i>Obesity</i> , 2013, 21, 2138-2145.	3.0	57
268	Mitochondrial Dysfunction as an Arrhythmogenic Substrate. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1466-1473.	2.8	112
269	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, CFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013, 58, 1941-1952.	7.3	355
270	Liver X Receptor Activation Stimulates Iron Export in Human Alternative Macrophages. <i>Circulation Research</i> , 2013, 113, 1196-1205.	4.5	76



#	ARTICLE	IF	CITATIONS
271	Palmitate increases <i>Nur77</i> expression by modulating ZBP89 and Sp1 binding to the <i>Nur77</i> proximal promoter in pancreatic $\beta$ cells. <i>FEBS Letters</i> , 2013, 587, 3883-3890.	2.8	13
272	PPAR $\alpha$ regulates the production of serum Vanin $\beta$ by liver. <i>FEBS Letters</i> , 2013, 587, 3742-3748.	2.8	56
273	Long-term prognostic value of preprocedural adiponectin levels in patients undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2013, 168, 4921-4924.	1.7	3
274	Profiling Serum Bile Acid Glucuronides in Humans: Gender Divergences, Genetic Determinants, and Response to Fenofibrate. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 533-543.	4.7	35
275	Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 177-183.	2.3	48
276	1334 CORRELATION OF HUMAN LIVER PPAR GENE EXPRESSION WITH HISTOLOGICAL SEVERITY OF NASH AND ASSOCIATED METABOLIC DERANGEMENTS: RATIONALE FOR TARGETED THERAPY. <i>Journal of Hepatology</i> , 2013, 58, S538.	3.7	0
277	Free leptin, carotid plaque phenotype and relevance to related symptomatology: Insights from the OPAL-Lille carotid endarterectomy study. <i>International Journal of Cardiology</i> , 2013, 168, 4879-4881.	1.7	2
278	Detrimental Effects of Diet-Induced Obesity on $\beta$ , Pathology Are Independent of Insulin Resistance in $\beta$ , Transgenic Mice. <i>Diabetes</i> , 2013, 62, 1681-1688.	0.6	88
279	11 $\beta$ -hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. <i>FASEB Journal</i> , 2013, 27, 1519-1531.	0.5	41
280	Macrophage Function and Polarization in Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1127-1134.	2.4	66
281	Activation of intestinal peroxisome proliferator-activated receptor- $\alpha$ increases high-density lipoprotein production. <i>European Heart Journal</i> , 2013, 34, 2566-2574.	2.2	44
282	Farnesoid X Receptor Inhibits the Transcriptional Activity of Carbohydrate Response Element Binding Protein in Human Hepatocytes. <i>Molecular and Cellular Biology</i> , 2013, 33, 2202-2211.	2.3	110
283	Fenofibrate Inhibits Endothelin-1 Expression by Peroxisome Proliferator-Activated Receptor $\beta$ -Dependent and Independent Mechanisms in Human Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 621-628.	2.4	28
284	Role of Proinflammatory CD68 <sup>+</sup> Mannose Receptor <sup>+</sup> Macrophages in Peroxiredoxin-1 Expression and in Abdominal Aortic Aneurysms in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 431-438.	2.4	65
285	Pharmacological interventions in human HDL metabolism. <i>Current Opinion in Lipidology</i> , 2013, 24, 500-509.	2.7	15
286	Retinoids and nuclear retinoid receptors in white and brown adipose tissues: physiopathologic aspects. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2013, 14, 75-86.	0.7	9
287	Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation. <i>Journal of Lipid Research</i> , 2013, 54, 1360-1368.	4.2	23
288	Increased Atherosclerotic Lesions in LDL Receptor Deficient Mice With Hematopoietic Nuclear Receptor Rev $\beta$ Knock-Down. <i>Journal of the American Heart Association</i> , 2013, 2, e000235.	3.7	44

#	ARTICLE	IF	CITATIONS
289	Dual Peroxisome Proliferator-Activated Receptor $\alpha/\delta$ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects. <i>Diabetes Care</i> , 2013, 36, 2923-2930.	8.6	187
290	Soaping Up Type 2 Diabetes With Bile Acids?. <i>Diabetes</i> , 2013, 62, 3987-3989.	0.6	11
291	Hepatic glucose sensing is required to preserve $\beta^2$ cell glucose competence. <i>Journal of Clinical Investigation</i> , 2013, 123, 1662-1676.	8.2	118
292	The Elongation Complex Components BRD4 and MLLT3/AF9 Are Transcriptional Coactivators of Nuclear Retinoid Receptors. <i>PLoS ONE</i> , 2013, 8, e64880.	2.5	14
293	PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke. <i>Current Drug Targets</i> , 2013, 14, 752-767.	2.1	23
294	Nur77 Turing Macrophages in Atherosclerosis. <i>Circulation Research</i> , 2012, 110, 375-377.	4.5	6
295	Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2012, 303, R135-R143.	1.8	95
296	Coordinated Regulation of PPAR Expression and Activity through Control of Chromatin Structure in Adipogenesis and Obesity. <i>PPAR Research</i> , 2012, 2012, 1-9.	2.4	32
297	PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 302, E1063-E1069.	3.5	76
298	The Novel Antibacterial Compound Walrycin A Induces Human PXR Transcriptional Activity. <i>Toxicological Sciences</i> , 2012, 127, 225-235.	3.1	9
299	Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. <i>Journal of Lipid Research</i> , 2012, 53, 1723-1737.	4.2	241
300	Genome-Wide Profiling of Liver X Receptor, Retinoid X Receptor, and Peroxisome Proliferator-Activated Receptor $\alpha$ in Mouse Liver Reveals Extensive Sharing of Binding Sites. <i>Molecular and Cellular Biology</i> , 2012, 32, 852-867.	2.3	205
301	Human Adipose Tissue Macrophages Display Activation of Cancer-related Pathways. <i>Journal of Biological Chemistry</i> , 2012, 287, 21904-21913.	3.4	60
302	Peroxisome Proliferator-Activated Receptor- $\beta$ Activation Induces 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 Activity in Human Alternative Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 677-685.	2.4	32
303	Impaired alternative macrophage differentiation of peripheral blood mononuclear cells from obese subjects. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 189-195.	2.0	43
304	General Molecular Biology and Architecture of Nuclear Receptors. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 486-504.	2.1	115
305	Response to the Letter by Finn et al. <i>Circulation Research</i> , 2012, 110, .	4.5	3
306	Peroxisome Proliferator-Activated Receptors- $\alpha$ and - $\beta$ , and cAMP-Mediated Pathways, Control Retinol-Binding Protein-4 Gene Expression in Brown Adipose Tissue. <i>Endocrinology</i> , 2012, 153, 1162-1173.	2.8	47

#	ARTICLE	IF	CITATIONS
307	Effect of Oxime Ether Incorporation in Acyl Indole Derivatives on PPAR Subtype Selectivity. <i>ChemMedChem</i> , 2012, 7, 2179-2193.	3.2	13
308	The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism. <i>Archives of Physiology and Biochemistry</i> , 2012, 118, 102-111.	2.1	46
309	Synthesis and evaluation of new polyenic compounds as potential PPARs modulators. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 6169.	2.8	9
310	The Nuclear Orphan Receptor Nur77 Is a Lipotoxicity Sensor Regulating Glucose-Induced Insulin Secretion in Pancreatic $\beta^2$ -Cells. <i>Molecular Endocrinology</i> , 2012, 26, 399-413.	3.7	38
311	Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation?. <i>Neuropharmacology</i> , 2012, 62, 784-796.	4.1	58
312	Thiazolidinediones and PPAR $\beta$ agonists: time for a reassessment. <i>Trends in Endocrinology and Metabolism</i> , 2012, 23, 205-215.	7.1	342
313	Control of metabolism by nutrient-regulated nuclear receptors acting in the brain. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 130, 126-137.	2.5	126
314	Roles of PPARs in NAFLD: Potential therapeutic targets. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2012, 1821, 809-818.	2.4	229
315	Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. <i>Cytokine</i> , 2012, 59, 442-449.	3.2	100
316	Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1365-1376.	3.6	65
317	LDL Receptor Knock-Out Mice Are a Physiological Model Particularly Vulnerable to Study the Onset of Inflammation in Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2012, 7, e30668.	2.5	135
318	Naturally improving insulin resistance with amorfrutins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 7136-7137.	7.1	10
319	Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers. <i>Nucleic Acids Research</i> , 2012, 40, 8255-8265.	14.5	166
320	DPP-4 inhibitors in the treatment of type 2 diabetes. <i>Biochemical Pharmacology</i> , 2012, 83, 823-832.	4.4	83
321	Bone Marrow p16INK4a-Deficiency Does Not Modulate Obesity, Glucose Homeostasis or Atherosclerosis Development. <i>PLoS ONE</i> , 2012, 7, e32440.	2.5	14
322	Which is the eligible patient to be treated with pioglitazone? The expert view. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 781-787.	3.3	1
323	PPAR $\beta$ Activation Induces Enteroendocrine L Cell GLP-1 Production. <i>Gastroenterology</i> , 2011, 140, 1564-1574.	1.3	55
324	Effects of the New Dual PPAR $\alpha/\beta$ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism. <i>Diabetes Care</i> , 2011, 34, 2008-2014.	8.6	155

#	ARTICLE	IF	CITATIONS
325	Short-term activation of liver X receptors inhibits osteoblasts but long-term activation does not have an impact on murine bone in vivo. <i>Bone</i> , 2011, 48, 339-346.	2.9	19
326	Liver X Receptor (LXR) activation negatively regulates visfatin expression in macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2011, 404, 458-462.	2.1	10
327	50 PPARA ACTIVATION DIFFERENTLY AFFECTS MICROPARTICLE CONTENT IN ATHEROSCLEROTIC LESIONS AND LIVER OF A MOUSE MODEL OF ATHEROSCLEROSIS AND NASH. <i>Atherosclerosis Supplements</i> , 2011, 12, 11.	1.2	0
328	446 ATHEROSCLEROTIC LESION REMODELLING IN REV-ERB $\beta$ -DEFICIENT MICE. <i>Atherosclerosis Supplements</i> , 2011, 12, 95.	1.2	0
329	PPAR $\beta$ activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. <i>Atherosclerosis</i> , 2011, 218, 69-76.	0.8	24
330	839 SERUM APOLIPOPROTEIN CIII LEVELS DECLINE AFTER WEIGHT LOSS INDUCED IMPROVEMENT IN HEPATIC STEATOSIS. <i>Journal of Hepatology</i> , 2011, 54, S335-S336.	3.7	0
331	Control of Gene Expression by the Retinoic Acid-Related Orphan Receptor Alpha in HepG2 Human Hepatoma Cells. <i>PLoS ONE</i> , 2011, 6, e22545.	2.5	27
332	Macrophage polarization in metabolic disorders. <i>Current Opinion in Lipidology</i> , 2011, 22, 365-372.	2.7	157
333	p16INK4a deficiency promotes IL-4 $\alpha$ -induced polarization and inhibits proinflammatory signaling in macrophages. <i>Blood</i> , 2011, 118, 2556-2566.	1.4	89
334	Overview of the Measurement of Lipids and Lipoproteins in Mice. <i>Current Protocols in Mouse Biology</i> , 2011, 1, 265-277.	1.2	2
335	Generation and characterization of a humanized PPAR $\gamma$ mouse model. <i>British Journal of Pharmacology</i> , 2011, 164, 192-208.	5.4	11
336	CIDEA interacts with liver X receptors in white fat cells. <i>FEBS Letters</i> , 2011, 585, 744-748.	2.8	9
337	Control of nuclear receptor activities in metabolism by post $\alpha$ translational modifications. <i>FEBS Letters</i> , 2011, 585, 1640-1650.	2.8	53
338	Downregulation of the tumour suppressor p16INK4A contributes to the polarisation of human macrophages toward an adipose tissue macrophage (ATM)-like phenotype. <i>Diabetologia</i> , 2011, 54, 3150-3156.	6.3	31
339	Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2011, 383, 423-436.	3.0	35
340	Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. <i>Neurobiology of Disease</i> , 2011, 43, 486-494.	4.4	137
341	Bile Acid Metabolism and the Pathogenesis of Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2011, 11, 160-166.	4.2	201
342	Obesity resistant mechanisms in the Lean polygenic mouse model as indicated by liver transcriptome and expression of selected genes in skeletal muscle. <i>BMC Genomics</i> , 2011, 12, 96.	2.8	14

#	ARTICLE	IF	CITATIONS
343	Coenzyme Q as an Antiadipogenic Factor. <i>Antioxidants and Redox Signaling</i> , 2011, 14, 403-413.	5.4	27
344	Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity. <i>Diabetes</i> , 2011, 60, 1861-1871.	0.6	261
345	Association Between a Thyroid Hormone Receptor- $\beta$ Gene Polymorphism and Blood Pressure but Not With Coronary Heart Disease Risk. <i>American Journal of Hypertension</i> , 2011, 24, 1027-1034.	2.0	12
346	Telomerase Activation in Atherosclerosis and Induction of Telomerase Reverse Transcriptase Expression by Inflammatory Stimuli in Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 245-252.	2.4	80
347	IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data. <i>Nucleic Acids Research</i> , 2011, 39, D534-D538.	14.5	96
348	Circadian Control of Epigenetic Modifications Modulates Metabolism. <i>Circulation Research</i> , 2011, 109, 353-355.	4.5	3
349	Peroxisome Proliferator-Activated Receptor- $\beta$ Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1573-1579.	2.4	66
350	Impaired Expression of the Inducible cAMP Early Repressor Accounts for Sustained Adipose CREB Activity in Obesity. <i>Diabetes</i> , 2011, 60, 3169-3174.	0.6	20
351	Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 513-519.	2.4	129
352	Human Atherosclerotic Plaque Alternative Macrophages Display Low Cholesterol Handling but High Phagocytosis Because of Distinct Activities of the PPAR $\beta$ and LXR $\beta$ Pathways. <i>Circulation Research</i> , 2011, 108, 985-995.	4.5	318
353	Antipsychotic drug action on SREBPs-related lipogenesis and cholesterologenesis in primary rat hepatocytes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010, 381, 427-439.	3.0	61
354	Characterization of new PPAR $\beta$ agonists: Benzimidazole derivatives' importance of positions 5 and 6, and computational studies on the binding mode. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5885-5895.	3.0	26
355	Bile Acid Sequestrants for Lipid and Glucose Control. <i>Current Diabetes Reports</i> , 2010, 10, 70-77.	4.2	68
356	Plasma bile acids are not associated with energy metabolism in humans. <i>Nutrition and Metabolism</i> , 2010, 7, 73.	3.0	67
357	Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. <i>FEBS Letters</i> , 2010, 584, 1001-1005.	2.8	93
358	The nuclear receptor FXR is expressed in pancreatic $\beta$ cells and protects human islets from lipotoxicity. <i>FEBS Letters</i> , 2010, 584, 2845-2851.	2.8	80
359	Kupffer cells promote hepatic steatosis via interleukin-1 $\beta$ -dependent suppression of peroxisome proliferator-activated receptor $\beta$ activity. <i>Hepatology</i> , 2010, 51, 511-522.	7.3	381
360	Visfatin is induced by peroxisome proliferator-activated receptor gamma in human macrophages. <i>FEBS Journal</i> , 2010, 277, 3308-3320.	4.7	24

#	ARTICLE	IF	CITATIONS
361	Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. <i>Laboratory Investigation</i> , 2010, 90, 1457-1467.	3.7	77
362	Brinster et al. reply. <i>Nature</i> , 2010, 463, E4-E4.	27.8	42
363	Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 384-392.	4.4	124
364	Krüppel-Like Factor KLF10 Is a Link between the Circadian Clock and Metabolism in Liver. <i>Molecular and Cellular Biology</i> , 2010, 30, 3059-3070.	2.3	95
365	Proteasomal degradation of retinoid X receptor $\beta$ reprograms transcriptional activity of PPAR $\beta$ in obese mice and humans. <i>Journal of Clinical Investigation</i> , 2010, 120, 1454-1468.	8.2	56
366	The Natural Protective Mechanism Against Hyperglycemia in Vascular Endothelial Cells. <i>Diabetes</i> , 2010, 59, 808-818.	0.6	67
367	Nuclear Receptors Linking Circadian Rhythms and Cardiometabolic Control. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1529-1534.	2.4	67
368	Introduction on the ATVB Review Series "Nuclear Receptors in Metabolism and Cardiovascular Disease". <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1504-1505.	2.4	1
369	Bile Acid Sequestrants: Glucose-Lowering Mechanisms. <i>Metabolic Syndrome and Related Disorders</i> , 2010, 8, S-3-S-8.	1.3	23
370	The Farnesoid X Receptor Regulates Adipocyte Differentiation and Function by Promoting Peroxisome Proliferator-activated Receptor- $\beta$ and Interfering with the Wnt/ $\beta$ -Catenin Pathways. <i>Journal of Biological Chemistry</i> , 2010, 285, 36759-36767.	3.4	79
371	SUMOylation of Human Peroxisome Proliferator-activated Receptor $\beta$ Inhibits Its Trans-activity through the Recruitment of the Nuclear Corepressor NCoR. <i>Journal of Biological Chemistry</i> , 2010, 285, 5983-5992.	3.4	78
372	Retinoid X receptors: common heterodimerization partners with distinct functions. <i>Trends in Endocrinology and Metabolism</i> , 2010, 21, 676-683.	7.1	258
373	Fibrates in CVD: a step towards personalised medicine. <i>Lancet, The</i> , 2010, 375, 1847-1848.	13.7	10
374	Fibrates, Glitazones, and Peroxisome Proliferator-Activated Receptors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 894-899.	2.4	172
375	Residual Risk Reduction Initiative: vã½zva ke snã¼4enã-reziduã;nãho vaskulã;nãho rizika u pacientã s dyslipidemiã: <i>Cor Et Vasa</i> , 2010, 52, 212-228.	0.1	0
376	Bile Acids and Metabolic Regulation. <i>Diabetes Care</i> , 2009, 32, S237-S245.	8.6	304
377	Tissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 548-554.	2.4	98
378	Despite Antiatherogenic Metabolic Characteristics, SCD1-Deficient Mice Have Increased Inflammation and Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 341-347.	2.4	95

#	ARTICLE	IF	CITATIONS
379	PPAR $\alpha$ blocks glucocorticoid receptor $\beta$ -mediated transactivation but cooperates with the activated glucocorticoid receptor $\beta$ for transrepression on NF- $\kappa$ B. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7397-7402.	7.1	102
380	Rev-erb $\alpha$ : an integrator of circadian rhythms and metabolism. Journal of Applied Physiology, 2009, 107, 1972-1980.	2.5	142
381	Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 12-18.	2.4	110
382	A Review of Bile Acid Sequestrants: Potential Mechanism(s) for Glucose-Lowering Effects in Type 2 Diabetes Mellitus. Postgraduate Medicine, 2009, 121, 25-30.	2.0	45
383	Rev-erb $\alpha$ mRNA Encodes a Stable Protein with a Potential Role in Circadian Clock Regulation. Molecular Endocrinology, 2009, 23, 630-639.	3.7	7
384	An Increased Flux through the Glucose 6-Phosphate Pool in Enterocytes Delays Glucose Absorption in Fxr-Deficient Mice. Journal of Biological Chemistry, 2009, 284, 10315-10323.	3.4	51
385	Retinoid Bexarotene Modulates Triglyceride but not Cholesterol Metabolism via Gene-Specific Permissivity of the RXR/LXR Heterodimer in the Liver. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1488-1495.	2.4	63
386	Morphologic and Electroretinographic Phenotype of SR-BI Knockout Mice after a Long-Term Atherogenic Diet. , 2009, 50, 3931.		35
387	Liver X receptor modulators: Effects on lipid metabolism and potential use in the treatment of atherosclerosis. Biochemical Pharmacology, 2009, 77, 1316-1327.	4.4	92
388	Inhibition of adipocyte differentiation by ROR $\alpha$ . FEBS Letters, 2009, 583, 2031-2036.	2.8	33
389	Characterization of New PPAR $\delta$ Agonists: Analysis of Telmisartan's Structural Components. ChemMedChem, 2009, 4, 445-456.	3.2	38
390	Characterization of New PPAR $\delta$ Agonists: Benzimidazole Derivatives - the Importance of Position...2. ChemMedChem, 2009, 4, 1136-1142.	3.2	22
391	Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. Acta Diabetologica, 2009, 46, 173-181.	2.5	22
392	Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease. Current Atherosclerosis Reports, 2009, 11, 281-288.	4.8	14
393	Effects of <i>Microdesmis keayana</i> alkaloids on vascular parameters of erectile dysfunction. Phytotherapy Research, 2009, 23, 892-895.	5.8	10
394	Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature, 2009, 458, 83-86.	27.8	273
395	Fenofibrate, a peroxisome proliferator-activated receptor $\alpha$ agonist, exerts anticonvulsive properties. Epilepsia, 2009, 50, 943-948.	5.1	47
396	4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPAR $\alpha/\delta$ agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2683-2687.	2.2	17

#	ARTICLE	IF	CITATIONS
397	Novel non-carboxylic acid retinoids: 1,2,4-Oxadiazol-5-one derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 489-492.	2.2	15
398	Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation. <i>Physiological Reviews</i> , 2009, 89, 147-191.	28.8	1,309
399	Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits. <i>Cardiovascular Pathology</i> , 2009, 18, 140-147.	1.6	18
400	Lipid ligand-activated transcription factors regulating lipid storage and release in human macrophages. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 486-493.	2.4	25
401	A pan-PPAR ligand induces hepatic fatty acid oxidation in PPAR $\alpha$ <sup>-/-</sup> /PPAR $\gamma$ <sup>-/-</sup> mice possibly through PGC-1 mediated PPAR $\gamma$ coactivation. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 1076-1083.	2.4	15
402	Unlike PPAR $\beta$ , PPAR $\alpha$ or PPAR $\gamma$ activation does not promote human monocyte differentiation toward alternative macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2009, 386, 459-462.	2.1	50
403	How to modulate FXR activity to treat the Metabolic Syndrome. <i>Drug Discovery Today Disease Mechanisms</i> , 2009, 6, e55-e64.	0.8	9
404	Tissue Factor Pathway Inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques. <i>Atherosclerosis</i> , 2009, 204, e4-e14.	0.8	40
405	On the mechanism for PPAR agonists to enhance ABCA1 gene expression. <i>Atherosclerosis</i> , 2009, 205, 413-419.	0.8	108
406	Fenofibrate Simultaneously Induces Hepatic Fatty Acid Oxidation, Synthesis, and Elongation in Mice. <i>Journal of Biological Chemistry</i> , 2009, 284, 34036-34044.	3.4	141
407	Combination therapy of statins and fibrates in the management of cardiovascular risk. <i>Current Opinion in Lipidology</i> , 2009, 20, 505-511.	2.7	45
408	Circumventing glucocorticoid-mediated hyperinsulinemia via the activation of PPAR $\alpha$ . <i>Cell Cycle</i> , 2009, 8, 2311-2312.	2.6	5
409	LEPOT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 3830-3838.	8.2	47
410	Peroxisome Proliferator-Activated Receptor- $\alpha$ Activation Protects Brain Capillary Endothelial Cells from Oxygen-Glucose Deprivation-Induced Hyperpermeability in the Blood-Brain Barrier. <i>Current Neurovascular Research</i> , 2009, 6, 181-193.	1.1	56
411	Technology-assisted learning: a longitudinal field study of knowledge category, learning effectiveness and satisfaction in language learning. <i>Journal of Computer Assisted Learning</i> , 2008, 24, 245-259.	5.1	87
412	Peroxisome proliferator-activated receptors "from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. <i>Journal of Internal Medicine</i> , 2008, 263, 28-42.	6.0	39
413	The glucocorticoid receptor is a coregulator of the orphan nuclear receptor Nurr1. <i>Journal of Neurochemistry</i> , 2008, 104, 777-789.	3.9	27
414	Modulating liver inflammation: a crucial role for cholesterol. <i>Chemistry and Physics of Lipids</i> , 2008, 154, S14.	3.2	0



#	ARTICLE	IF	CITATIONS
415	Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. <i>Hepatology</i> , 2008, 48, 474-486.	7.3	413
416	4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPAR $\alpha/\delta$ agonists. Part I: Synthesis and pharmacological evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1617-1622.	2.2	36
417	A central role for cholesterol metabolism and inflammation during the inhibition of non-alcoholic steatohepatitis with a synthetic PPAR $\alpha$ agonist. <i>Chemistry and Physics of Lipids</i> , 2008, 154, S56.	3.2	0
418	Association between liver X receptor $\alpha$ gene polymorphisms and risk of metabolic syndrome in French populations. <i>International Journal of Obesity</i> , 2008, 32, 421-428.	3.4	30
419	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 102, 1K-34K.	1.6	371
420	Rev $\alpha$ gives a time cue to metabolism. <i>FEBS Letters</i> , 2008, 582, 19-25.	2.8	84
421	Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. <i>FEBS Letters</i> , 2008, 582, 949-955.	2.8	89
422	Cross-talk Between Statins and PPAR $\alpha$ in Cardiovascular Diseases: Clinical Evidence and Basic Mechanisms. <i>Trends in Cardiovascular Medicine</i> , 2008, 18, 73-78.	4.9	51
423	Regulation of Bile Acid Synthesis by the Nuclear Receptor Rev $\alpha$ . <i>Gastroenterology</i> , 2008, 135, 689-698.e5.	1.3	175
424	Peroxisome proliferator-activated receptor $\alpha$ regulates skin inflammation and humoral response in atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 962-968.e6.	2.9	69
425	Vasoactivity, antioxidant and aphrodisiac properties of <i>Caesalpinia benthamiana</i> roots. <i>Journal of Ethnopharmacology</i> , 2008, 116, 112-119.	4.1	27
426	STATINS INCREASE EXPRESSION OF PLA2G7 IN MOUSE PERITONEAL MACROPHAGES. <i>Atherosclerosis Supplements</i> , 2008, 9, 201.	1.2	0
427	Apolipoprotein CIII. <i>Circulation Research</i> , 2008, 103, 1348-1350.	4.5	13
428	Liver-Specific Peroxisome Proliferator-Activated Receptor $\alpha$ Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan. <i>Diabetes</i> , 2008, 57, 1405-1413.	0.6	74
429	Liver X Receptor Activation Induces the Uptake of Cholesteryl Esters From High Density Lipoproteins in Primary Human Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 2288-2295.	2.4	28
430	Suppression of Pro-inflammatory Adhesion Molecules by PPAR $\delta$ in Human Vascular Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 315-321.	2.4	137
431	Cardiac hypertrophy is enhanced in PPAR $\alpha$ <sup>-/-</sup> mice in response to chronic pressure overload. <i>Cardiovascular Research</i> , 2008, 78, 79-89.	3.8	116
432	Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. <i>Journal of Lipid Research</i> , 2008, 49, 217-229.	4.2	59

#	ARTICLE	IF	CITATIONS
433	PPARs/RXRs in Cardiovascular Physiology and Disease. <i>PPAR Research</i> , 2008, 2008, 1-1.	2.4	12
434	The nuclear receptors Rev-erbs and RORs integrate circadian rhythms and metabolism. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 82-88.	2.0	111
435	Regulation of Macrophage Functions by PPAR- $\alpha$ , PPAR- $\beta$ , and LXRs in Mice and Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1050-1059.	2.4	262
436	Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells. <i>Biochemical Journal</i> , 2008, 410, 245-253.	3.7	49
437	The PPAR- $\alpha$ /p16 <sup>INK4a</sup> Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycle-Dependent Telomerase Activation. <i>Circulation Research</i> , 2008, 103, 1155-1163.	4.5	61
438	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 319-335.	2.0	227
439	Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia. <i>Circulation Research</i> , 2008, 103, 450-453.	4.5	33
440	Induction of CXCR2 Receptor by Peroxisome Proliferator-Activated Receptor $\beta$ in Human Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 932-939.	2.4	23
441	Systemic and Distal Repercussions of Liver-Specific Peroxisome Proliferator-Activated Receptor- $\alpha$ Control of the Acute-Phase Response. <i>Endocrinology</i> , 2008, 149, 3215-3223.	2.8	53
442	Fibrates and future PPAR- $\alpha$ agonists in the treatment of cardiovascular disease. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 542-553.	3.3	141
443	The Nuclear Receptor Rev-erb $\alpha$ Is a Liver X Receptor (LXR) Target Gene Driving a Negative Feedback Loop on Select LXR-Induced Pathways in Human Macrophages. <i>Molecular Endocrinology</i> , 2008, 22, 1797-1811.	3.7	54
444	Intestine-Specific Regulation of PPAR- $\alpha$ Gene Transcription by Liver X Receptors. <i>Endocrinology</i> , 2008, 149, 5128-5135.	2.8	29
445	Phosphorylation of Farnesoid X Receptor by Protein Kinase C Promotes Its Transcriptional Activity. <i>Molecular Endocrinology</i> , 2008, 22, 2433-2447.	3.7	66
446	ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. <i>Journal of Clinical Investigation</i> , 2008, 118, 956-64.	8.2	158
447	Liver X Receptor Activation Potentiates the Lipopolysaccharide Response in Human Macrophages. <i>Circulation Research</i> , 2007, 101, 40-49.	4.5	117
448	Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 145-156.	2.8	136
449	IAP Survivin Regulates Atherosclerotic Macrophage Survival. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 901-907.	2.4	34
450	The PPAR- $\alpha$ Activator Fenofibrate Slows Down the Progression of the Left Ventricular Dysfunction in Porcine Tachycardia-Induced Cardiomyopathy. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 49, 408-415.	1.9	61

#	ARTICLE	IF	CITATIONS
451	The farnesoid X receptor induces fetuin-B gene expression in human hepatocytes. <i>Biochemical Journal</i> , 2007, 407, 461-469.	3.7	17
452	Peroxisome Proliferator-Activated Receptor $\beta$ and Adipose Tissue Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 386-395.	3.6	423
453	Measuring biomarkers to assess the therapeutic effects of PPAR agonists?. <i>Pharmacogenomics</i> , 2007, 8, 1567-1580.	1.3	4
454	Inhibition of progesterone production in human luteinized granulosa cells treated with LXR agonists. <i>Molecular Human Reproduction</i> , 2007, 13, 373-379.	2.8	37
455	Retinoid-related orphan receptor $\alpha$ regulates several genes that control metabolism in skeletal muscle cells: links to modulation of reactive oxygen species production. <i>Journal of Molecular Endocrinology</i> , 2007, 39, 29-44.	2.5	40
456	Inter-subject differences in constitutive expression levels of the clock gene in man. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, 39-43.	2.0	14
457	Peroxisome Proliferator-Activated Receptors Mediate Pleiotropic Actions of Statins. <i>Circulation Research</i> , 2007, 100, 1394-1395.	4.5	33
458	S 26948: a New Specific Peroxisome Proliferator Activated Receptor $\alpha$ Modulator With Potent Antidiabetes and Antiatherogenic Effects. <i>Diabetes</i> , 2007, 56, 2797-2808.	0.6	50
459	PPAR Agonists and the Metabolic Syndrome. <i>Therapie</i> , 2007, 62, 319-326.	1.0	37
460	Transcriptional regulation of macrophage cholesterol trafficking by PPAR $\alpha$ and LXR. <i>Biochemical Society Transactions</i> , 2007, 35, 165-165.	3.4	0
461	Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. <i>Current Opinion in Lipidology</i> , 2007, 18, 289-297.	2.7	53
462	The orphan nuclear receptor Rev-erb $\beta$ : a transcriptional link between circadian rhythmicity and cardiometabolic disease. <i>Current Opinion in Lipidology</i> , 2007, 18, 141-146.	2.7	31
463	FXR: a promising target for the metabolic syndrome?. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 236-243.	8.7	136
464	Safety issues and prospects for future generations of PPAR modulators. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2007, 1771, 1065-1081.	2.4	255
465	PPAR $\gamma$ , but not PPAR $\alpha$ , activates PGC-1 $\beta$ gene transcription in muscle. <i>Biochemical and Biophysical Research Communications</i> , 2007, 354, 1021-1027.	2.1	110
466	IP receptor-dependent activation of PPAR $\beta$ by stable prostacyclin analogues. <i>Biochemical and Biophysical Research Communications</i> , 2007, 360, 821-827.	2.1	59
467	PPAR $\beta$ Activation Primes Human Monocytes into Alternative M2 Macrophages with Anti-inflammatory Properties. <i>Cell Metabolism</i> , 2007, 6, 137-143.	16.2	1,125
468	The core component of the mammalian SWI/SNF complex SMARCD3/BAF60c is a coactivator for the nuclear retinoic acid receptor. <i>Molecular and Cellular Endocrinology</i> , 2007, 270, 23-32.	3.2	41

#	ARTICLE	IF	CITATIONS
469	Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques. <i>Atherosclerosis</i> , 2007, 195, e117-e125.	0.8	19
470	FXR deficiency confers increased susceptibility to torpor. <i>FEBS Letters</i> , 2007, 581, 5191-5198.	2.8	30
471	PPAR Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2007, 56, 1662-1670.	0.6	65
472	Bile Acid Sequestrants and the Treatment of Type 2 Diabetes Mellitus. <i>Drugs</i> , 2007, 67, 1383-1392.	10.9	149
473	PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2007, 21, 687-710.	4.7	170
474	Genetically-engineered animals as research models for atherosclerosis : their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 4132.	3.0	10
475	Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor $\alpha$ agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4689-4693.	2.2	76
476	Glitazones in the treatment of cardiovascular risk factors. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 7-13.	1.9	3
477	Metformin and pioglitazone: effectively treating insulin resistance. <i>Current Medical Research and Opinion</i> , 2006, 22, S27-S37.	1.9	44
478	Overview of Nomenclature of Nuclear Receptors. <i>Pharmacological Reviews</i> , 2006, 58, 685-704.	16.0	540
479	Mo-W6:1 Metabolic and vascular control by lipid-sensing nuclear receptors: Role of the peroxisome proliferator-activated receptor-alpha as a mediator of the pleiotropic effects of statins. <i>Atherosclerosis Supplements</i> , 2006, 7, 20-21.	1.2	0
480	Th-W60:3 Acute anti-inflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the PKC signalling pathway. <i>Atherosclerosis Supplements</i> , 2006, 7, 487.	1.2	1
481	Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. <i>Journal of Endocrinology</i> , 2006, 189, 199-209.	2.6	173
482	Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2006, 48, A24-A32.	2.8	35
483	Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. <i>Biochemical and Biophysical Research Communications</i> , 2006, 340, 1259-1263.	2.1	156
484	PPAR $\alpha$ and PPAR $\beta$ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. <i>Current Opinion in Pharmacology</i> , 2006, 6, 606-614.	3.5	176
485	Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. <i>Journal of Hepatology</i> , 2006, 44, 732-741.	3.7	213
486	The expanding role of the bile acid receptor FXR in the small intestine. <i>Journal of Hepatology</i> , 2006, 44, 1213-1215.	3.7	16

#	ARTICLE	IF	CITATIONS
487	Transcriptional regulation of macrophage cholesterol trafficking by PPAR $\alpha$ and LXR. <i>Biochemical Society Transactions</i> , 2006, 34, 1128-1131.	3.4	21
488	Sorting out the roles of PPAR $\alpha$ in energy metabolism and vascular homeostasis. <i>Journal of Clinical Investigation</i> , 2006, 116, 571-580.	8.2	779
489	PPARs in Atherosclerosis. , 2006, , 159-179.		1
490	Human retinoic acid receptor-related orphan receptor $\gamma$ 1 overexpression protects neurones against oxidative stress-induced apoptosis. <i>Journal of Neurochemistry</i> , 2006, 96, 1778-1789.	3.9	84
491	When the Clock stops ticking, metabolic syndrome explodes. <i>Nature Medicine</i> , 2006, 12, 54-55.	30.7	144
492	Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPAR $\delta$ agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 7377-7391.	3.0	18
493	Studies towards the conception of new selective PPAR $\delta$ / $\gamma$ ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4528-4532.	2.2	17
494	Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 379-401.	2.4	91
495	The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. <i>Diabetologia</i> , 2006, 49, 527-537.	6.3	64
496	[4-(2H-1,2,3-Benzotriazol-2-yl)phenoxy]alkanoic Acids as Agonists of Peroxisome Proliferator-Activated Receptors (PPARs). <i>Chemistry and Biodiversity</i> , 2006, 3, 385-395.	2.1	9
497	The liver X-receptor alpha controls hepatic expression of the human bile acid-glucuronidating UGT1A3 enzyme in human cells and transgenic mice. <i>Hepatology</i> , 2006, 44, 368-378.	7.3	64
498	Paullinia pinnata Extracts Rich in Polyphenols Promote Vascular Relaxation via Endothelium-dependent Mechanisms. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 599-608.	1.9	44
499	FXR: More than a Bile Acid Receptor?. <i>Endocrinology</i> , 2006, 147, 4022-4024.	2.8	8
500	Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 845-850.	2.4	61
501	Peroxisome Proliferator-Activated Receptor $\delta$ Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets. <i>Diabetes</i> , 2006, 55, 1605-1613.	0.6	100
502	PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. <i>Biochemical Society Transactions</i> , 2006, 34, 1341-1346.	3.4	263
503	Cholesterol $7\alpha$ -Hydroxylase Deficiency in Mice on an APOE*3-Leiden Background Increases Hepatic ABCA1 mRNA Expression and HDL-Cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2724-2730.	2.4	8
504	Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR $\alpha$ Activators. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 977-986.	2.4	154

#	ARTICLE	IF	CITATIONS
505	The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice. <i>Journal of Biological Chemistry</i> , 2006, 281, 11039-11049.	3.4	463
506	Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferator-Activated Receptor- $\alpha$ via Inhibition of the Protein Kinase C Signaling Pathway. <i>Circulation Research</i> , 2006, 98, 361-369.	4.5	157
507	TREP-132 Is a Novel Progesterone Receptor Coactivator Required for the Inhibition of Breast Cancer Cell Growth and Enhancement of Differentiation by Progesterone. <i>Molecular and Cellular Biology</i> , 2006, 26, 7632-7644.	2.3	29
508	Transcription Factor TCF7L2 Genetic Study in the French Population: Expression in Human $\beta$ -Cells and Adipose Tissue and Strong Association With Type 2 Diabetes. <i>Diabetes</i> , 2006, 55, 2903-2908.	0.6	300
509	Both Hepatic and Extrahepatic ABCA1 Have Discrete and Essential Functions in the Maintenance of Plasma High-Density Lipoprotein Cholesterol Levels In Vivo. <i>Circulation</i> , 2006, 114, 1301-1309.	1.6	80
510	International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors. <i>Pharmacological Reviews</i> , 2006, 58, 726-741.	16.0	869
511	Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c. <i>Journal of Biological Chemistry</i> , 2006, 281, 6211-6218.	3.4	260
512	The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed Dyslipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2731-2737.	2.4	69
513	Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. <i>Journal of Clinical Investigation</i> , 2006, 116, 1052-1062.	8.2	447
514	Molecular Characterization of New Selective Peroxisome Proliferator-Activated Receptor $\alpha$ Modulators With Angiotensin Receptor Blocking Activity. <i>Diabetes</i> , 2005, 54, 3442-3452.	0.6	270
515	The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 65-72.	4.4	198
516	Pro-inflammatory properties for thiazolidinediones. <i>Biochemical Pharmacology</i> , 2005, 69, 255-265.	4.4	23
517	Pleiotropic effects of fibrates. <i>Current Atherosclerosis Reports</i> , 2005, 7, 396-401.	4.8	39
518	The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition. <i>Journal of Biological Chemistry</i> , 2005, 280, 29971-29979.	3.4	186
519	Reduced cholesterol absorption upon PPAR $\gamma$ activation coincides with decreased intestinal expression of NPC1L1. <i>Journal of Lipid Research</i> , 2005, 46, 526-534.	4.2	161
520	Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor. <i>Molecular and Cellular Biology</i> , 2005, 25, 1537-1548.	2.3	88
521	Hepatic Expression of the UGT1A9 Gene Is Governed by Hepatocyte Nuclear Factor $\alpha$ . <i>Molecular Pharmacology</i> , 2005, 67, 241-249.	2.3	61
522	The Farnesoid X Receptor. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2020-2030.	2.4	425

#	ARTICLE	IF	CITATIONS
523	Peroxisome proliferator-activated receptor $\alpha$ controls cellular cholesterol trafficking in macrophages. <i>Journal of Lipid Research</i> , 2005, 46, 2717-2725.	4.2	60
524	Complete functional rescue of the ABCA1 <sup>-/-</sup> mouse by human BAC transgenesis. <i>Journal of Lipid Research</i> , 2005, 46, 1113-1123.	4.2	11
525	A fully dissociated compound of plant origin for inflammatory gene repression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 15827-15832.	7.1	245
526	Farnesoid X Receptor: A New Player in Glucose Metabolism?. <i>Endocrinology</i> , 2005, 146, 981-983.	2.8	38
527	PPAR $\alpha$ , but not PPAR $\beta$ , Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1897-1902.	2.4	70
528	TReP-132 Controls Cell Proliferation by Regulating the Expression of the Cyclin-Dependent Kinase Inhibitors p21WAF1/Cip1 and p27Kip1. <i>Molecular and Cellular Biology</i> , 2005, 25, 4335-4348.	2.3	25
529	The Gene Encoding Acyl-CoA-binding Protein Is Subject to Metabolic Regulation by Both Sterol Regulatory Element-binding Protein and Peroxisome Proliferator-activated Receptor $\alpha$ in Hepatocytes. <i>Journal of Biological Chemistry</i> , 2005, 280, 5258-5266.	3.4	44
530	Review: Vascular protective effects of peroxisome proliferator-activated receptor agonists. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 126-132.	0.6	2
531	Liver X Receptor Activation Controls Intracellular Cholesterol Trafficking and Esterification in Human Macrophages. <i>Circulation Research</i> , 2005, 97, 682-689.	4.5	108
532	The Gene Encoding Fibrinogen- $\beta$ Is a Target for Retinoic Acid Receptor-Related Orphan Receptor $\alpha$ . <i>Molecular Endocrinology</i> , 2005, 19, 2517-2526.	3.7	12
533	W15-IS-001 PPARs as targets for anti-atherosclerotic therapies. <i>Atherosclerosis Supplements</i> , 2005, 6, 95.	1.2	0
534	W15-IS-002 Role of farnesoid X receptor (FXR) in control of plasma lipid levels. <i>Atherosclerosis Supplements</i> , 2005, 6, 95-96.	1.2	0
535	W15-O-003 Atheroprotective effect of the rexinoid targretin in a murine model of atherosclerosis. <i>Atherosclerosis Supplements</i> , 2005, 6, 96.	1.2	1
536	Therapeutical effects of PPAR agonists assessed by biomarker modulation. <i>Biomarkers</i> , 2005, 10, 30-36.	1.9	9
537	Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor $\alpha$ Modulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 585-591.	2.4	116
538	PPAR $\beta$ and atherosclerosis. <i>Current Medical Research and Opinion</i> , 2005, 21, S13-S20.	1.9	68
539	Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear Receptor ROR $\alpha$ . <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1186-1192.	2.4	50
540	Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2005, 1738, 48-53.	2.4	9

#	ARTICLE	IF	CITATIONS
541	Fluid retention mediated by renal PPAR $\beta$ . <i>Cell Metabolism</i> , 2005, 2, 77-78.	16.2	47
542	Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. <i>Current Opinion in Pharmacology</i> , 2005, 5, 177-183.	3.5	84
543	Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. <i>Biochimie</i> , 2005, 87, 93-98.	2.6	32
544	The role of the orphan nuclear receptor Rev-Erb $\beta$ in adipocyte differentiation and function. <i>Biochimie</i> , 2005, 87, 21-25.	2.6	48
545	Pancreatic islet response to hyperglycemia is dependent on peroxisome proliferator-activated receptor alpha (PPAR $\alpha$ ). <i>FEBS Letters</i> , 2005, 579, 2284-2288.	2.8	21
546	Transient impairment of the adaptive response to fasting in FXR-deficient mice. <i>FEBS Letters</i> , 2005, 579, 4076-4080.	2.8	72
547	Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene. <i>FEBS Letters</i> , 2005, 579, 5535-5541.	2.8	30
548	Peroxisome Proliferator-Activated Receptor $\beta$ : A novel target for the reduction of atherosclerosis. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2005, 2, 237-243.	0.5	7
549	Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists. <i>Diabetes</i> , 2005, 54, 2460-2470.	0.6	575
550	Synthesis, Biological Evaluation, and Molecular Modeling Investigation of New Chiral Fibrates with PPAR $\alpha$ and PPAR $\beta$ Agonist Activity. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5509-5519.	6.4	52
551	PPAR $\alpha$ inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. <i>Journal of Clinical Investigation</i> , 2005, 115, 3228-3238.	8.2	145
552	PPAR $\alpha$ deficiency does not modify age dependency but prevents high fat diet increase in plasma PAI-1 as well as insulin resistance. <i>Thrombosis and Haemostasis</i> , 2004, 91, 1051-1052.	3.4	4
553	Ala <sup>12</sup> Ala Genotype of the Peroxisome Proliferator-Activated Receptor $\beta$ Protects against Atherosclerosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4238-4242.	3.6	58
554	Peroxisome Proliferator-Activated Receptors and Atherogenesis. <i>Circulation Research</i> , 2004, 94, 1168-1178.	4.5	471
555	The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor $\beta$ . <i>Molecular Endocrinology</i> , 2004, 18, 1906-1918.	3.7	97
556	The farnesoid X receptor: a novel drug target?. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1135-1148.	4.1	39
557	Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse. <i>Journal of Lipid Research</i> , 2004, 45, 543-550.	4.2	44
558	Peroxisome Proliferator-Activated Receptor $\alpha$ Induces NADPH Oxidase Activity in Macrophages, Leading to the Generation of LDL with PPAR $\alpha$ Activation Properties. <i>Circulation Research</i> , 2004, 95, 1174-1182.	4.5	108



#	ARTICLE	IF	CITATIONS
559	Regulation of Endothelial Nitric Oxide Synthase by PPAR Agonists: Molecular and Clinical Perspectives. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 619-621.	2.4	12
560	Farnesoid X receptor represses hepatic lipase gene expression. <i>Journal of Lipid Research</i> , 2004, 45, 2110-2115.	4.2	43
561	PPAR $\alpha$ Activators Inhibit Vascular Endothelial Growth Factor Receptor-2 Expression by Repressing Sp1-Dependent DNA Binding and Transactivation. <i>Circulation Research</i> , 2004, 94, 324-332.	4.5	105
562	Statin Induction of Liver Fatty Acid-Binding Protein (L-FABP) Gene Expression Is Peroxisome Proliferator-activated Receptor $\alpha$ -dependent. <i>Journal of Biological Chemistry</i> , 2004, 279, 45512-45518.	3.4	84
563	The transcriptional regulating protein of 132 kDa (TRP-132) differentially influences steroidogenic pathways in human adrenal NCI-H295 cells. <i>Journal of Molecular Endocrinology</i> , 2004, 32, 557-569.	2.5	10
564	Hepatic de Novo Synthesis of Glucose 6-Phosphate Is Not Affected in Peroxisome Proliferator-activated Receptor $\alpha$ -Deficient Mice but Is Preferentially Directed toward Hepatic Glycogen Stores after a Short Term Fast. <i>Journal of Biological Chemistry</i> , 2004, 279, 8930-8937.	3.4	38
565	Glucose Regulates the Expression of the Farnesoid X Receptor in Liver. <i>Diabetes</i> , 2004, 53, 890-898.	0.6	226
566	Metabolic syndrome without obesity: Hepatic overexpression of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 in transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 7088-7093.	7.1	399
567	Estrogen-Related Receptor $\alpha$ Directs Peroxisome Proliferator-Activated Receptor $\alpha$ Signaling in the Transcriptional Control of Energy Metabolism in Cardiac and Skeletal Muscle. <i>Molecular and Cellular Biology</i> , 2004, 24, 9079-9091.	2.3	436
568	Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor $\alpha$ Activator Fenofibrate. <i>Journal of Biological Chemistry</i> , 2004, 279, 16154-16160.	3.4	182
569	Novel Adipose Tissue $\alpha$ -Mediated Resistance to Diet-Induced Visceral Obesity in 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 $\alpha$ -Deficient Mice. <i>Diabetes</i> , 2004, 53, 931-938.	0.6	476
570	Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPAR $\alpha$ and PPAR $\gamma$ agonists. <i>International Journal of Clinical Practice</i> , 2004, 58, 22-29.	1.7	35
571	The Farnesoid X Receptor (FXR) as Modulator of Bile Acid Metabolism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2004, 5, 319-326.	5.7	58
572	Different ways to regulate the PPAR $\alpha$ ; stability. <i>Biochemical and Biophysical Research Communications</i> , 2004, 319, 663-663.	2.1	0
573	The farnesoid X receptor induces very low density lipoprotein receptor gene expression. <i>FEBS Letters</i> , 2004, 566, 173-177.	2.8	91
574	Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPAR $\alpha$ , PPAR $\gamma$ , and LXR. <i>Biochemical and Biophysical Research Communications</i> , 2004, 314, 151-158.	2.1	239
575	Different ways to regulate the PPAR $\alpha$ stability. <i>Biochemical and Biophysical Research Communications</i> , 2004, 319, 663-670.	2.1	33
576	Genomic and non-genomic interactions of PPAR $\alpha$ with xenobiotic-metabolizing enzymes. <i>Trends in Endocrinology and Metabolism</i> , 2004, 15, 324-330.	7.1	33

#	ARTICLE	IF	CITATIONS
577	PPAR $\alpha$ controlling HDL metabolism and atherosclerosis. International Congress Series, 2004, 1262, 215-219.	0.2	0
578	Fenofibrate Increases Homocystinemia Through a PPAR $\alpha$ -Mediated Mechanism. Journal of Cardiovascular Pharmacology, 2004, 43, 452-453.	1.9	30
579	Lesion Progression in apoE-Deficient Mice: Implication of Chemokines and Effect of the AT1 Angiotensin II Receptor Antagonist Irbesartan. Journal of Cardiovascular Pharmacology, 2004, 43, 191-199.	1.9	20
580	Inhibition of cytokine production by the herbicide atrazine. Biochemical Pharmacology, 2003, 65, 303-308.	4.4	18
581	Expression and Localization of Peroxisome Proliferator-Activated Receptors and Nuclear Factor $\kappa$ B in Normal and Lesional Psoriatic Skin. Journal of Investigative Dermatology, 2003, 121, 1104-1117.	0.7	105
582	Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications. International Journal of Obesity, 2003, 27, S41-S45.	3.4	90
583	Induction of hepatic ABC transporter expression is part of the PPAR $\alpha$ -mediated fasting response in the mouse. Gastroenterology, 2003, 124, 160-171.	1.3	79
584	A Paradigm for Gene Regulation: Inflammation, NF- $\kappa$ B and PPAR. Advances in Experimental Medicine and Biology, 2003, 544, 181-196.	1.6	199
585	FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology, 2003, 124, 1926-1940.	1.3	176
586	Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology, 2003, 125, 544-555.	1.3	235
587	Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Trends in Pharmacological Sciences, 2003, 24, 530-534.	8.7	26
588	Peroxisome proliferator-activator receptor- $\alpha$ activator (PPAR- $\alpha$ ) dose not inhibit the activation of human hepatic stellate cells by IL-1 $\beta$ . Journal of Hepatology, 2003, 38, 82.	3.7	0
589	Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1631, 107-118.	2.4	80
590	Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1631, 218-228.	2.4	27
591	Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. Journal of Steroid Biochemistry and Molecular Biology, 2003, 85, 267-273.	2.5	262
592	Expression and Functional Role of Peroxisome Proliferator-Activated Receptor- $\beta$ in Ovarian Folliculogenesis in the Sheep1. Biology of Reproduction, 2003, 69, 1665-1674.	2.7	83
593	Peroxisome Proliferator-activated Receptors $\alpha$ and $\beta$ Down-regulate Allergic Inflammation and Eosinophil Activation. Journal of Experimental Medicine, 2003, 198, 411-421.	8.5	239
594	Peroxisome Proliferator-Activated Receptor (PPAR) $\alpha$ and PPAR $\beta/\delta$ , but not PPAR $\gamma$ , Modulate the Expression of Genes Involved in Cardiac Lipid Metabolism. Circulation Research, 2003, 92, 518-524.	4.5	389

#	ARTICLE	IF	CITATIONS
595	Peroxisome Proliferator-Activated Receptor $\alpha$ Reduces Cholesterol Esterification in Macrophages. <i>Circulation Research</i> , 2003, 92, 212-217.	4.5	107
596	Peroxisome Proliferator-activated Receptor $\alpha$ Induces Hepatic Expression of the Human Bile Acid Glucuronidating UDP-glucuronosyltransferase 2B4 Enzyme. <i>Journal of Biological Chemistry</i> , 2003, 278, 32852-32860.	3.4	123
597	Bile Acids Induce the Expression of the Human Peroxisome Proliferator-Activated Receptor $\alpha$ Gene via Activation of the Farnesoid X Receptor. <i>Molecular Endocrinology</i> , 2003, 17, 259-272.	3.7	391
598	The Orphan Nuclear Receptor Rev-Erb $\alpha$ Is a Peroxisome Proliferator-activated Receptor (PPAR) $\alpha$ Target Gene and Promotes PPAR $\alpha$ -induced Adipocyte Differentiation. <i>Journal of Biological Chemistry</i> , 2003, 278, 37672-37680.	3.4	215
599	The Two Variants of Oxysterol Binding Protein-related Protein-1 Display Different Tissue Expression Patterns, Have Different Intracellular Localization, and Are Functionally Distinct. <i>Molecular Biology of the Cell</i> , 2003, 14, 903-915.	2.1	100
600	The UDP-glucuronosyltransferase 1A9 Enzyme Is a Peroxisome Proliferator-activated Receptor $\alpha$ and $\beta$ Target Gene. <i>Journal of Biological Chemistry</i> , 2003, 278, 13975-13983.	3.4	113
601	Peroxisome Proliferator-Activated Receptor $\beta$ Inhibits the Migration of Dendritic Cells: Consequences for the Immune Response. <i>Journal of Immunology</i> , 2003, 170, 5295-5301.	0.8	85
602	Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor $\alpha$ Activators. <i>Journal of Biological Chemistry</i> , 2003, 278, 17982-17985.	3.4	186
603	Fibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice. <i>Journal of Biological Chemistry</i> , 2003, 278, 7884-7890.	3.4	115
604	PPARs and atherosclerosis. <i>Advances in Molecular and Cell Biology</i> , 2003, 33, 543-560.	0.1	0
605	Rupture of the Atherosclerotic Plaque. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 535-542.	2.4	107
606	Liver X receptors: new players in atherogenesis?. <i>Current Opinion in Lipidology</i> , 2003, 14, 137-143.	2.7	18
607	Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. <i>Current Opinion in Lipidology</i> , 2003, 14, 459-468.	2.7	83
608	Fibrates down-regulate IL-1 $\alpha$ -stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NF $\kappa$ B/C/EBP $\beta$ complex formation. <i>Blood</i> , 2003, 101, 545-551.	1.4	211
609	Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. <i>Biochemical Journal</i> , 2003, 369, 539-547.	3.7	150
610	Potential roles of ROR $\alpha$ in cardiovascular endocrinology. <i>Nuclear Receptor Signaling</i> , 2003, 1, nrs.01011.	1.0	8
611	Different short- and long-term effects of resveratrol on nuclear factor- $\kappa$ B phosphorylation and nuclear appearance in human endothelial cells. <i>American Journal of Clinical Nutrition</i> , 2003, 77, 1220-1228.	4.7	73
612	Ppar-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis. <i>Progress in Experimental Cardiology</i> , 2003, , 3-16.	0.0	3

#	ARTICLE	IF	CITATIONS
613	Peroxisome Proliferator-Activated Receptor- $\alpha$ Activation as a Mechanism of Preventive Neuroprotection Induced by Chronic Fenofibrate Treatment. <i>Journal of Neuroscience</i> , 2003, 23, 6264-6271.	3.6	212
614	Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 717-726.	2.4	388
615	Transcriptional Regulation of Human Rev-erb $\alpha$ Gene Expression by the Orphan Nuclear Receptor Retinoic Acid-related Orphan Receptor $\alpha$ . <i>Journal of Biological Chemistry</i> , 2002, 277, 49275-49281.	3.4	60
616	Efficient Gene Regulation by PPAR $\alpha$ and Thiazolidinediones in Skeletal Muscle and Heart. <i>Molecular Therapy</i> , 2002, 6, 265-271.	8.2	5
617	Rosiglitazone, a Peroxisome Proliferator-Activated Receptor- $\alpha$ , Inhibits the Jun NH2-Terminal Kinase/Activating Protein 1 Pathway and Protects the Heart From Ischemia/Reperfusion Injury. <i>Diabetes</i> , 2002, 51, 1507-1514.	0.6	173
618	Peroxisome Proliferator-Activated Receptor $\alpha$ Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease. <i>Circulation</i> , 2002, 105, 1440-1445.	1.6	136
619	Peroxisome Proliferator-Activated Receptor $\alpha$ Gene Regulates Left Ventricular Growth in Response to Exercise and Hypertension. <i>Circulation</i> , 2002, 105, 950-955.	1.6	149
620	Peroxisome Proliferator-activated Receptor $\alpha$ (PPAR $\alpha$ ) Turnover by the Ubiquitin-Proteasome System Controls the Ligand-induced Expression Level of Its Target Genes. <i>Journal of Biological Chemistry</i> , 2002, 277, 37254-37259.	3.4	121
621	Peroxisome Proliferator-activated Receptor Activators Inhibit Oxidized Low-density Lipoprotein-induced Endothelin-1 Secretion in Endothelial Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2002, 40, 822-831.	1.9	83
622	FUNCTION OF THE TRANSCRIPTIONAL REGULATING PROTEIN OF 132 kDa (TReP-132) ON HUMAN P450 <sub>scc</sub> GENE EXPRESSION. <i>Endocrine Research</i> , 2002, 28, 559-574.	1.2	10
623	DNA Binding-Independent Induction of $\alpha$ Gene Transcription by PPAR $\alpha$ . <i>Molecular Endocrinology</i> , 2002, 16, 1029-1039.	3.7	95
624	PPAR $\alpha$ Inhibits TGF- $\beta$ -Induced $\alpha$ 5 Integrin Transcription in Vascular Smooth Muscle Cells by Interacting With Smad4. <i>Circulation Research</i> , 2002, 91, e35-44.	4.5	62
625	Identification of Rev-erb $\alpha$ as a physiological repressor of apoC-III gene transcription. <i>Journal of Lipid Research</i> , 2002, 43, 2172-2179.	4.2	159
626	The Transcriptional Regulating Protein of 132 kDa (TReP-132) Enhances P450 <sub>scc</sub> Gene Transcription through Interaction with Steroidogenic Factor-1 in Human Adrenal Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 39144-39155.	3.4	52
627	Human Sterol 27-Hydroxylase (CYP27) Overexpressor Transgenic Mouse Model. <i>Journal of Biological Chemistry</i> , 2002, 277, 34036-34041.	3.4	65
628	Rôles des Peroxisome Proliferator-Activated Receptors (PPARs) dans la régulation du métabolisme des lipides et le contrôle de l'inflammation. <i>Société De Biologie Journal</i> , 2002, 196, 47-52.	0.3	35
629	HMG-CoA reductase inhibition and PPAR-alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. <i>Clinical Science</i> , 2002, 103, 81S-83S.	4.3	10
630	Dietary trans-10,cis-12 conjugated linoleic acid induces hyperinsulinemia and fatty liver in the mouse. <i>Journal of Lipid Research</i> , 2002, 43, 1400-1409.	4.2	308

#	ARTICLE	IF	CITATIONS
631	Characterization of the Human PPAR $\alpha$ Promoter: Identification of a Functional Nuclear Receptor Response Element. <i>Molecular Endocrinology</i> , 2002, 16, 1013-1028.	3.7	144
632	Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor $\alpha$ Agonist Fenofibrate in Mice. <i>Journal of Biological Chemistry</i> , 2002, 277, 48051-48057.	3.4	174
633	Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages. <i>FEBS Letters</i> , 2002, 512, 85-90.	2.8	69
634	The role of PPARs in atherosclerosis. <i>Trends in Molecular Medicine</i> , 2002, 8, 422-430.	6.7	228
635	Age-related phenotypes in the staggerer mouse expand the ROR $\alpha$ nuclear receptor's role beyond the cerebellum. <i>Molecular and Cellular Endocrinology</i> , 2002, 186, 1-5.	3.2	68
636	The clinical significance of PPAR $\alpha$ and $\beta$ agonism. <i>British Journal of Diabetes and Vascular Disease</i> , 2002, 2, S28-S31.	0.6	6
637	Extracorporeal albumin dialysis (MARS) improves cholestasis and normalizes low apo A-I levels in a patient with benign recurrent intrahepatic cholestasis (BRIC). <i>Liver</i> , 2002, 22, 72-75.	0.1	40
638	A cholesterol tether. <i>Nature</i> , 2002, 417, 699-701.	27.8	28
639	PPARs: Transcription Factors Controlling Lipid and Lipoprotein Metabolism. <i>Annals of the New York Academy of Sciences</i> , 2002, 967, 7-18.	3.8	148
640	Role of PPARs in Inflammation, Atherosclerosis, and Thrombosis. <i>Medical Science Symposia Series</i> , 2002, , 25-34.	0.0	1
641	Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. <i>Journal of Lipid Research</i> , 2002, 43, 742-750.	4.2	45
642	Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. <i>Journal of Clinical Investigation</i> , 2002, 109, 961-971.	8.2	244
643	Increased ABCA1 activity protects against atherosclerosis. <i>Journal of Clinical Investigation</i> , 2002, 110, 35-42.	8.2	216
644	Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. <i>Journal of Clinical Investigation</i> , 2002, 109, 961-971.	8.2	110
645	Increased ABCA1 activity protects against atherosclerosis. <i>Journal of Clinical Investigation</i> , 2002, 110, 35-42.	8.2	121
646	Increased ABCA1 activity protects against atherosclerosis. <i>Journal of Clinical Investigation</i> , 2002, 110, 35-42.	8.2	57
647	DNA Binding-Independent Induction of $\beta$ Gene Transcription by PPAR $\alpha$ . <i>Molecular Endocrinology</i> , 2002, 16, 1029-1039.	3.7	59
648	PPAR $\alpha$ , Lipoprotein Metabolism, Metabolic Diseases, and Atherosclerosis. <i>Medical Science Symposia Series</i> , 2002, , 63-79.	0.0	0

#	ARTICLE	IF	CITATIONS
649	Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. Journal of Lipid Research, 2002, 43, 742-50.	4.2	42
650	PPARs in Inflammation, Atherosclerosis and Thrombosis. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 187-194.	2.8	40
651	Ppars, metabolic disease and atherosclerosis. Pharmacological Research, 2001, 44, 345-352.	7.1	110
652	Regulation of lipid and lipoprotein metabolism by retinoids. Journal of the American Academy of Dermatology, 2001, 45, S158-S167.	1.2	66
653	New roles for PPARs in cholesterol homeostasis. Trends in Pharmacological Sciences, 2001, 22, 444.	8.7	2
654	Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice reduces atherogenesis in response to a high fat-high cholesterol diet. FEBS Letters, 2001, 502, 16-20.	2.8	16
655	Angiotensin AT1 Receptor Antagonist Irbesartan Decreases Lesion Size, Chemokine Expression, and Macrophage Accumulation in Apolipoprotein E-Deficient Mice. Journal of Cardiovascular Pharmacology, 2001, 38, 395-405.	1.9	91
656	Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Current Opinion in Lipidology, 2001, 12, 245-254.	2.7	182
657	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 187-194.	1.5	66
658	Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor $\hat{\pm}$ down-regulate platelet-activating-factor receptor expression in human macrophages. Biochemical Journal, 2001, 354, 225.	3.7	23
659	Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor $\hat{\pm}$ down-regulate platelet-activating-factor receptor expression in human macrophages. Biochemical Journal, 2001, 354, 225-232.	3.7	27
660	The role of fibric acids in atherosclerosis. Current Atherosclerosis Reports, 2001, 3, 83-92.	4.8	164
661	Peroxisome proliferator-activated receptor $\hat{3}$ activators affect the maturation of human monocyte-derived dendritic cells. European Journal of Immunology, 2001, 31, 2857-2865.	2.9	212
662	Schistosoma mansoni induces the synthesis of IL-6 in pulmonary microvascular endothelial cells: role of IL-6 in the control of lung eosinophilia during infection. European Journal of Immunology, 2001, 31, 2751-2761.	2.9	33
663	The orphan nuclear receptor ROR $\hat{\pm}$ is a negative regulator of the inflammatory response. EMBO Reports, 2001, 2, 42-48.	4.5	259
664	PPAR- $\hat{\pm}$ and PPAR- $\hat{3}$ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine, 2001, 7, 53-58.	30.7	1,075
665	Lack of toxic effects of F 12511, a novel potent inhibitor of acyl-coenzyme A: cholesterol O-acyltransferase, on human adrenocortical cells in culture <sup>11</sup> Abbreviations: ACAT, acyl-coenzyme A: cholesterol O-acyltransferase; F 12511, (S)-2- $\hat{\epsilon}$ ,3- $\hat{\epsilon}$ ,5- $\hat{\epsilon}$ -trimethyl-4- $\hat{\epsilon}$ -hydroxy- $\hat{\pm}$ -dodecylthio-phenylacetanilide; DMEM, Dulbecco's modified Eagle medium; FBS, fetal bovine serum; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SR-BI, scavenger receptor class B, type I; P450 <sub>sc</sub> , cytochrome P450 cholesterol side-chain. Biochemical Pharmacology, 2001, 61, 387-398.	4.4	18
666	Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor $\hat{\pm}$ Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein $\hat{2}$ . Journal of Biological Chemistry, 2001, 276, 33471-33477.	3.4	140

#	ARTICLE	IF	CITATIONS
667	Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator-Activated Receptor- $\alpha$ -Mediated Downregulation of Cholesterol 7 $\alpha$ -Hydroxylase and Sterol 27-Hydroxylase Expression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1840-1845.	2.4	185
668	Peroxisome proliferator-activated receptors in inflammation control. <i>Journal of Endocrinology</i> , 2001, 169, 453-459.	2.6	697
669	Peroxisome Proliferator-activated Receptor- $\alpha$ Regulates Lipid Homeostasis, but Is Not Associated with Obesity. <i>Journal of Biological Chemistry</i> , 2001, 276, 39088-39093.	3.4	119
670	Improved Lipid and Lipoprotein Profile, Hepatic Insulin Sensitivity, and Glucose Tolerance in 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 Null Mice. <i>Journal of Biological Chemistry</i> , 2001, 276, 41293-41300.	3.4	395
671	Human ABCA1 BAC Transgenic Mice Show Increased High Density Lipoprotein Cholesterol and ApoA1-dependent Efflux Stimulated by an Internal Promoter Containing Liver X Receptor Response Elements in Intron 1. <i>Journal of Biological Chemistry</i> , 2001, 276, 33969-33979.	3.4	176
672	Induction of the Phospholipid Transfer Protein Gene Accounts for the High Density Lipoprotein Enlargement in Mice Treated with Fenofibrate. <i>Journal of Biological Chemistry</i> , 2001, 276, 25841-25847.	3.4	84
673	PPAR- $\alpha$ Null Mice Are Protected From High-Fat Diet-Induced Insulin Resistance. <i>Diabetes</i> , 2001, 50, 2809-2814.	0.6	228
674	Transcriptional Regulation of Apolipoprotein C-III Gene Expression by the Orphan Nuclear Receptor ROR $\alpha$ . <i>Journal of Biological Chemistry</i> , 2001, 276, 2865-2871.	3.4	129
675	PPAR $\alpha$ Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages. <i>Circulation</i> , 2001, 103, 207-212.	1.6	197
676	Peroxisome Proliferator-activated Receptor $\alpha$ Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil. <i>Journal of Biological Chemistry</i> , 2001, 276, 4634-4639.	3.4	70
677	The OSBP-related protein family in humans. <i>Journal of Lipid Research</i> , 2001, 42, 1203-1213.	4.2	177
678	Statin-induced inhibition of the Rho-signaling pathway activates PPAR $\alpha$ and induces HDL apoA-I. <i>Journal of Clinical Investigation</i> , 2001, 107, 1423-1432.	8.2	381
679	Nouvelles conceptions sur le mode d'action des fibrates et perspectives thérapeutiques de l'athérosclérose. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2001, 185, 63-75.	0.0	3
680	PPAR (peroxisome proliferator-activated receptors) et paroi vasculaire : implications dans l'athérosclérose. <i>Medecine/Sciences</i> , 2001, 17, 637.	0.2	0
681	Peroxisome Proliferator-activated Receptor $\alpha$ Activators Improve Insulin Sensitivity and Reduce Adiposity. <i>Journal of Biological Chemistry</i> , 2000, 275, 16638-16642.	3.4	554
682	Nuclear transcription factors: new opportunities for lipid lowering. <i>Proceedings of the Nutrition Society</i> , 2000, 59, 433-433.	1.0	1
683	Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. <i>Biochemical Pharmacology</i> , 2000, 60, 1245-1250.	4.4	202
684	Variation in the PPAR $\alpha$ gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. <i>Diabetologia</i> , 2000, 43, 673-680.	6.3	180

#	ARTICLE	IF	CITATIONS
685	Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. <i>Inflammation Research</i> , 2000, 49, 497-505.	4.0	853
686	Circadian and Glucocorticoid Regulation of Rev-erb $\beta$ Expression in Liver. <i>Endocrinology</i> , 2000, 141, 3799-3806.	2.8	150
687	CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors. <i>Circulation</i> , 2000, 101, 2411-2417.	1.6	405
688	Induction of Rev-erb $\beta$ Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor- $\alpha$ Activators. <i>Journal of Biological Chemistry</i> , 2000, 275, 36703-36707.	3.4	417
689	Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 3-11.	2.3	225
690	Oxidized phospholipids activate PPAR $\alpha$ in a phospholipase A2-dependent manner. <i>FEBS Letters</i> , 2000, 471, 34-38.	2.8	179
691	Peroxisome proliferator-activated receptor $\beta$ activators inhibit interleukin-12 production in murine dendritic cells. <i>FEBS Letters</i> , 2000, 486, 261-266.	2.8	152
692	Le rôle de ses activateurs dans la régulation de l'expression des gènes impliqués dans le métabolisme des lipoprotéines, l'inflammation vasculaire et l'athérosclérose. <i>Annales De L'Institut Pasteur / Actualités</i> , 2000, 11, 89-106.	0.1	0
693	Induction of MDR2 P-glycoprotein (PGP) by fibrates is mediated by peroxisome proliferator-activated receptor alpha (PPAR $\alpha$ ) in the mouse. <i>Journal of Hepatology</i> , 2000, 32, 119.	3.7	1
694	PPARs and Atherosclerosis. , 2000, , 88-95.		1
695	Circadian and Glucocorticoid Regulation of Rev-erb $\beta$ Expression in Liver. <i>Endocrinology</i> , 2000, 141, 3799-3806.	2.8	25
696	Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation of the Peroxisome Proliferator-Activated Receptor- $\alpha$ . <i>Blood</i> , 1999, 93, 2991-2998.	1.4	127
697	Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. <i>Current Opinion in Lipidology</i> , 1999, 10, 245-258.	2.7	386
698	Fibrates Increase Human REV-ERB $\beta$ Expression in Liver via a Novel Peroxisome Proliferator-Activated Receptor Response Element. <i>Molecular Endocrinology</i> , 1999, 13, 400-409.	3.7	132
699	A Truncated Human Peroxisome Proliferator-Activated Receptor $\beta$ Splice Variant with Dominant Negative Activity. <i>Molecular Endocrinology</i> , 1999, 13, 1535-1549.	3.7	126
700	Peroxisome Proliferator-Activated Receptor Activators Inhibit Thrombin-Induced Endothelin-1 Production in Human Vascular Endothelial Cells by Inhibiting the Activator Protein-1 Signaling Pathway. <i>Circulation Research</i> , 1999, 85, 394-402.	4.5	489
701	Beneficial Effects of Fibrates on Apolipoprotein A-I Metabolism Occur Independently of Any Peroxisome Proliferative Response. <i>Circulation</i> , 1999, 99, 2445-2451.	1.6	52
702	Developmental and Pharmacological Regulation of Apolipoprotein C-II Gene Expression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 115-121.	2.4	39



#	ARTICLE	IF	CITATIONS
703	No short-term effect of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses LP-A-I and LP-A-I:A-II in healthy volunteers. <i>Journal of Internal Medicine</i> , 1999, 246, 120-122.	6.0	3
704	Protective Role of Interleukin-10 in Atherosclerosis. <i>Circulation Research</i> , 1999, 85, e17-24.	4.5	631
705	The mitochondrion is the principal target for nutritional and pharmacological control of plasma triglyceride. <i>Lipids</i> , 1999, 34, S167-S167.	1.7	3
706	Effects of <i>Pinus pinaster</i> and <i>Pinus koraiensis</i> seed oil supplementation on lipoprotein metabolism in the rat. <i>Lipids</i> , 1999, 34, 39-44.	1.7	176
707	Comparison of expression and regulation of the high-density lipoprotein receptor SR-BI and the low-density lipoprotein receptor in human adrenocortical carcinoma NCI-H295 cells. <i>FEBS Journal</i> , 1999, 261, 481-491.	0.2	56
708	<i>Schistosoma mansoni</i> schistosomula reduce E-selectin and VCAM-1 expression in TNF- $\alpha$ -stimulated lung microvascular endothelial cells by interfering with the NF- $\kappa$ B pathway. <i>European Journal of Immunology</i> , 1999, 29, 3691-3701.	2.9	44
709	Peroxisome Proliferator-activated Receptor $\alpha$ Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF- $\kappa$ B and AP-1. <i>Journal of Biological Chemistry</i> , 1999, 274, 32048-32054.	3.4	982
710	11. Nuclear receptors as targets to modulate HDL levels. <i>Atherosclerosis</i> , 1999, 146, S15.	0.8	0
711	Fibrates suppress bile acid synthesis via PPAR $\alpha$ -mediated down-regulation of cholesterol 7 $\alpha$ -hydroxylase and sterol 27-hydroxylase gene expression. <i>Atherosclerosis</i> , 1999, 144, 23.	0.8	1
712	Effects of F 12511, a potent ACAT inhibitor, on human adrenocortical cells in culture. <i>Atherosclerosis</i> , 1999, 144, 28.	0.8	0
713	Hypolipidemic effects of R103757, a potent stereoselective inhibitor of microsomal triglyceride transfer protein (MTP). <i>Atherosclerosis</i> , 1999, 144, 38.	0.8	4
714	Regulation of CLA-1 (CD36 and limp II analogous I) by activators of peroxisome proliferator activated receptors (PPARS). <i>Atherosclerosis</i> , 1999, 144, 112.	0.8	2
715	Regulation of macrophage lipoprotein lipase expression by activators of peroxisome proliferator-activated receptors. <i>Atherosclerosis</i> , 1999, 144, 146.	0.8	1
716	Cell Culture Conditions Determine Apolipoprotein CIII Secretion and Regulation by Fibrates in Human Hepatoma HepG2 Cells. <i>Cellular Physiology and Biochemistry</i> , 1999, 9, 139-149.	1.6	38
717	Metabolism of Apolipoproteins AI and AII in a Patient with Paradoxical Reduction in High-Density Lipoprotein Due to Ciprofibrate. <i>Annals of Clinical Biochemistry</i> , 1999, 36, 523-525.	1.6	26
718	Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. <i>Current Opinion in Lipidology</i> , 1999, 10, 151-160.	2.7	210
719	Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation of the Peroxisome Proliferator-Activated Receptor- $\alpha$ . <i>Blood</i> , 1999, 93, 2991-2998.	1.4	39
720	Fibrates Increase Human REV-ERB $\alpha$ Expression in Liver via a Novel Peroxisome Proliferator-Activated Receptor Response Element. <i>Molecular Endocrinology</i> , 1999, 13, 400-409.	3.7	87

#	ARTICLE	IF	CITATIONS
721	A Truncated Human Peroxisome Proliferator-Activated Receptor $\alpha$ Splice Variant with Dominant Negative Activity. <i>Molecular Endocrinology</i> , 1999, 13, 1535-1549.	3.7	88
722	La mutation staggerer du r�cepteur nucl�aire ROR $\alpha$ , ou comment un ph�notype peut en cacher un autre.. <i>Medecine/Sciences</i> , 1999, 15, 1305.	0.2	0
723	Activation of human aortic smooth-muscle cells is inhibited by PPAR $\alpha$ but not by PPAR $\beta$ activators. <i>Nature</i> , 1998, 393, 790-793.	27.8	1,104
724	Leptin. <i>Lancet</i> , The, 1998, 351, 737-742.	13.7	430
725	High level expression of PPAR $\beta$ in differentiated colon epithelium. <i>Gastroenterology</i> , 1998, 114, A391.	1.3	0
726	Regulation of apo A-I gene expression by fibrates. <i>Atherosclerosis</i> , 1998, 137, S19-S23.	0.8	112
727	PPAR $\beta$ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. <i>Atherosclerosis</i> , 1998, 137, S75-S80.	0.8	119
728	Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor $\alpha$ -dependent pathway. <i>Toxicology Letters</i> , 1998, 98, 13-23.	0.8	72
729	Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. <i>Circulation</i> , 1998, 98, 2088-2093.	1.6	1,540
730	Activation of Proliferator-activated Receptors $\alpha$ and $\beta$ Induces Apoptosis of Human Monocyte-derived Macrophages. <i>Journal of Biological Chemistry</i> , 1998, 273, 25573-25580.	3.4	837
731	The Nuclear Receptors Peroxisome Proliferator-activated Receptor $\alpha$ and Rev-erb $\alpha$ Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates. <i>Journal of Biological Chemistry</i> , 1998, 273, 25713-25720.	3.4	270
732	Severe Atherosclerosis and Hypoalphalipoproteinemia in the Staggerer Mouse, a Mutant of the Nuclear Receptor ROR $\alpha$ . <i>Circulation</i> , 1998, 98, 2738-2743.	1.6	166
733	Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.. <i>Journal of Clinical Investigation</i> , 1998, 102, 625-632.	8.2	120
734	Mechanisms of the Hypolipidemic Action of Fibrates. <i>Medical Science Symposia Series</i> , 1998, , 9-17.	0.0	0
735	Transcription of the Human Genes for Cytochrome P450 $\alpha$ and P450 $\beta$ Is Regulated Differently in Human Adrenal NCI-H295 Cells Than in Mouse Adrenal Y1 Cells1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 365-371.	3.6	81
736	Transcriptional Regulation of Apolipoprotein A-I Gene Expression by the Nuclear Receptor ROR $\alpha$ . <i>Journal of Biological Chemistry</i> , 1997, 272, 22401-22404.	3.4	127
737	The Organization, Promoter Analysis, and Expression of the Human PPAR $\beta$ Gene. <i>Journal of Biological Chemistry</i> , 1997, 272, 18779-18789.	3.4	1,034
738	Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPAR $\alpha$ and PPAR $\beta$ Activators. <i>Journal of Biological Chemistry</i> , 1997, 272, 28210-28217.	3.4	464

#	ARTICLE	IF	CITATIONS
739	Peroxisome proliferator-activated receptors, orphans with ligands and functions. <i>Current Opinion in Lipidology</i> , 1997, 8, 159-166.	2.7	455
740	Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor $\alpha$ -deficient Mice. <i>Journal of Biological Chemistry</i> , 1997, 272, 27307-27312.	3.4	388
741	4.P.304 HDL (high density lipoprotein) and LDL (low density lipoprotein) receptors regulation in human adrenal cortex. <i>Atherosclerosis</i> , 1997, 134, 360.	0.8	0
742	4.P.367 Transcription factor genes controlling high density lipoprotein metabolism. <i>Atherosclerosis</i> , 1997, 134, 374.	0.8	0
743	4.P.263 Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPAR $\alpha$ and PPAR $\beta$ activators. <i>Atherosclerosis</i> , 1997, 134, 351.	0.8	0
744	1.P.174 The mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. <i>Atherosclerosis</i> , 1997, 134, 53.	0.8	0
745	1.P.194 Thiazolidinediones exert a hypotriglyceridemic effect by a distinct, but complementary mechanism relative to fibrates. <i>Atherosclerosis</i> , 1997, 134, 57-58.	0.8	1
746	1.P.199 The underlying mechanism of the hypolipidemic effect of 3-thia fatty acids. <i>Atherosclerosis</i> , 1997, 134, 58-59.	0.8	0
747	2.P.139 Effects of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses lpA-I and lpA-I: A-II in healthy volunteers. <i>Atherosclerosis</i> , 1997, 134, 145.	0.8	0
748	The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). <i>Biochimie</i> , 1997, 79, 95-99.	2.6	71
749	Cycle Sequencing on Large DNA Templates. <i>BioTechniques</i> , 1997, 23, 1034-1036.	1.8	10
750	Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 1756-1764.	2.4	142
751	Transcription of the Human Genes for Cytochrome P450 $\alpha$ and P450 $\beta$ Is Regulated Differently in Human Adrenal NCI-H295 Cells Than in Mouse Adrenal Y1 Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 365-371.	3.6	60
752	Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. <i>Diabetes</i> , 1997, 46, 1319-1327.	0.6	171
753	Rôle des cofacteurs transcriptionnels dans la transduction des signaux hormonaux par les récepteurs nucléaires. <i>Medecine/Sciences</i> , 1997, 13, 961.	0.2	0
754	The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. <i>Lipids and Lipid Metabolism</i> , 1996, 1302, 93-109.	2.6	900
755	Transcription, adipocyte differentiation, and obesity. <i>Journal of Molecular Medicine</i> , 1996, 74, 347-352.	3.9	67
756	Growth hormone normalizes low-density lipoprotein receptor gene expression in hypothyroid rats. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 680-685.	3.4	14

#	ARTICLE	IF	CITATIONS
757	Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. <i>Atherosclerosis</i> , 1996, 124, S29-S37.	0.8	140
758	Regulation of Triglyceride Metabolism by PPARs : Fibrates and Thiazolidinediones have Distinct Effects. <i>Journal of Atherosclerosis and Thrombosis</i> , 1996, 3, 81-89.	2.0	104
759	Two regulatory elements of similar structure and placed in tandem account for the repressive activity of the first intron of the human apolipoprotein A-II gene. <i>Biochemical Journal</i> , 1996, 318, 547-553.	3.7	16
760	The adipocyte specific transcription factor C/EBPalpha modulates human ob gene expression.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 5507-5511.	7.1	139
761	New insights into obesity genes. <i>Diabetologia</i> , 1996, 39, 1528-1531.	6.3	6
762	Transcriptional Induction of Rat Liver Apolipoprotein A-I Gene Expression by Glucocorticoids Requires the Glucocorticoid Receptor and a Labile Cell-Specific Protein. <i>FEBS Journal</i> , 1996, 239, 451-459.	0.2	26
763	PPAR Tissue Distribution and Interactions with Other Hormone-Signaling Pathways. <i>Annals of the New York Academy of Sciences</i> , 1996, 804, 231-251.	3.8	149
764	Expression and Regulation of the Lipoprotein Lipase Gene in Human Adrenal Cortex. <i>Journal of Biological Chemistry</i> , 1996, 271, 17425-17432.	3.4	10
765	Expression of the Peroxisome Proliferator-activated Receptor $\delta$ Gene Is Stimulated by Stress and Follows a Diurnal Rhythm. <i>Journal of Biological Chemistry</i> , 1996, 271, 1764-1769.	3.4	291
766	Regulation of OB Gene Expression in Rodents and Humans. <i>Hormone and Metabolic Research</i> , 1996, 28, 638-641.	1.5	38
767	Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.. <i>Journal of Clinical Investigation</i> , 1996, 97, 2408-2416.	8.2	230
768	The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue.. <i>Journal of Clinical Investigation</i> , 1996, 98, 251-255.	8.2	162
769	Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma.. <i>Journal of Clinical Investigation</i> , 1996, 98, 1004-1009.	8.2	318
770	Les facteurs r�gulateurs du g�ne ob. <i>Medecine/Sciences</i> , 1996, 12, 383.	0.2	0
771	Transcription, diff�renciation adipocytaire et ob�sit�. <i>Medecine/Sciences</i> , 1996, 12, 885.	0.2	0
772	Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter. <i>Journal of Biological Chemistry</i> , 1995, 270, 19269-19276.	3.4	344
773	Regulation of Rat Liver Apolipoprotein A-I, Apolipoprotein A-II and Acyl-Coenzyme A Oxidase Gene Expression by Fibrates and Dietary Fatty Acids. <i>FEBS Journal</i> , 1995, 232, 179-187.	0.2	121
774	Transient increase in obese gene expression after food intake or insulin administration. <i>Nature</i> , 1995, 377, 527-528.	27.8	1,063

#	ARTICLE	IF	CITATIONS
775	Localization of the Human OB Gene (OBS) to Chromosome 7q32 by Fluorescence in Situ Hybridization. <i>Genomics</i> , 1995, 28, 603-604.	2.9	26
776	Induction of ob Gene Expression by Corticosteroids Is Accompanied by Body Weight Loss and Reduced Food Intake. <i>Journal of Biological Chemistry</i> , 1995, 270, 15958-15961.	3.4	410
777	Tissue-specific Expression of the Human Gene for Lecithin: Cholesterol Acyltransferase in Transgenic Mice Alters Blood Lipids, Lipoproteins and Lipases towards a Less Atherogenic Profile. <i>FEBS Journal</i> , 1995, 230, 567-575.	0.2	53
778	Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.. <i>Journal of Clinical Investigation</i> , 1995, 95, 705-712.	8.2	381
779	Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.. <i>Journal of Clinical Investigation</i> , 1995, 96, 741-750.	8.2	350
780	Opposite in vitro and in vivo regulation of hepatic apolipoprotein A-I gene expression by retinoic acid. Absence of effects on apolipoprotein A-II gene expression.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1994, 14, 1657-1664.	3.9	32
781	Acyl-CoA synthetase mRNA expression is controlled by fibric acid derivatives, feeding and liver proliferation. <i>FEBS Journal</i> , 1993, 216, 615-622.	0.2	100
782	Growth hormone normalizes hepatic lipase in hypothyroid rat liver. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 669-671.	3.4	5
783	Developmental extinction of liver lipoprotein lipase mRNA expression might be regulated by an NF-1-like site. <i>FEBS Letters</i> , 1993, 329, 89-95.	2.8	21
784	Effects of Sex Steroids on Hepatic and Lipoprotein Lipase Activity and mRNA in the Rat. <i>Hormone Research</i> , 1993, 40, 184-188.	1.8	26
785	Basal transcriptional activity and cyclic adenosine 3',5'-monophosphate responsiveness of the human cytochrome P450 <sub>sc</sub> promoter transfected into MA-10 Leydig cells. <i>Endocrinology</i> , 1993, 132, 546-552.	2.8	13
786	Regulation of steroidogenesis in NCI-H295 cells: a cellular model of the human fetal adrenal. <i>Molecular Endocrinology</i> , 1993, 7, 423-433.	3.7	93
787	Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1992, 12, 286-294.	3.9	142
788	Lipoprotein lipase expression in undifferentiated hepatoma cells is regulated by progesterone and protein kinase A. <i>Biochemistry</i> , 1992, 31, 10121-10128.	2.5	15
789	Down-regulation of hepatic lipase gene expression and activity by fenofibrate. <i>Lipids and Lipid Metabolism</i> , 1992, 1123, 227-230.	2.6	32
790	Opposite regulation of hepatic lipase and lecithin: cholesterol acyltransferase by glucocorticoids in rats. <i>Lipids and Lipid Metabolism</i> , 1992, 1128, 181-185.	2.6	34
791	Neonatal extinction of liver lipoprotein lipase expression. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1992, 1131, 281-286.	2.4	30
792	Changes in IgG Fc receptor expression induced by phorbol 12-myristate 13-acetate treatment of THP-1 monocytic leukemia cells. <i>Leukemia Research</i> , 1992, 16, 317-327.	0.8	43

#	ARTICLE	IF	CITATIONS
793	The effects of probucol on lipoprotein metabolism in the rat. <i>Lipids and Lipid Metabolism</i> , 1991, 1085, 131-135.	2.6	8
794	Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1991, 11, 760-769.	3.9	58
795	Increased removal of beta-very low density lipoproteins after ethinyl estradiol is associated with increased mRNA levels for hepatic lipase, lipoprotein lipase, and the low density lipoprotein receptor in Watanabe heritable hyperlipidemic rabbits.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1991, 11, 1652-1659.	3.9	18
796	Activation of junB by PKC and PKA signal transduction through a novel cis-acting element. <i>Nucleic Acids Research</i> , 1991, 19, 775-781.	14.5	95
797	Alterations in Thyroid Status Modulate Apolipoprotein, Hepatic Triglyceride Lipase, and Low Density Lipoprotein Receptor in Rats*. <i>Endocrinology</i> , 1990, 127, 1144-1152.	2.8	129
798	Coupled and uncoupled induction of fos and jun transcription by different second messengers in cells of hematopoietic origin. <i>Nucleic Acids Research</i> , 1990, 18, 221-228.	14.5	74
799	Apolipoprotein A-IV Messenger Ribonucleic Acid Abundance Is Regulated in a Tissue-Specific Manner*. <i>Endocrinology</i> , 1990, 126, 2153-2163.	2.8	66